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Abstract

Huntingtin aggregation at interfaces associated with membranes and organelles

Adewale Adegbuyiro
Huntington’s Disease (HD) is a genetic neurodegenerative disease caused by the
expansion of polyglutamine (polyQ) domain within the first exon (exon1) of the huntingtin
(htt) protein. Due to this mutation within the polyQ domain, htt aggregates into various
toxic species such as oligomers, fibrils, and other amorphous aggregates. While the
aggregation of htt strongly correlates with polyQ length, other factors, e.g. interaction with
membranes or organelles and posttranslational modifications (PTMs), modulate
aggregation. The first 17 N-terminal amino acids (Nt17) that precede the polyQ in httexon1 enhances aggregation and facilitated binding of htt to membranous organelles,
promoting morphological changes and disfunction. In addition, several PTMs occur within
Nt17, including oxidation. Here, mechanistic insights into the impact of mitochondrial
association and oxidation of htt-exon1 on its aggregation are presented. To investigate
how htt aggregation is altered in the presence of mitochondria, htt-exon1 with an
expanded polyQ domain was exposed to mitochondria membrane mimics and
mitochondria enriched fractions (MEFs). Mitochondrial membrane mimics significantly
reduced htt aggregation into fibrils. However, inner mitochondrial membrane mimic (IMM)
had a greater inhibitory effect on htt-exon1 fibrillization compared with outer mitochondrial
membrane mimic (OMM). Cardiolipin, a mitochondria-exclusive-lipid that is more
abundant in IMM, played a primary role in altering htt aggregation. Similarly, MEFs
suppressed fibril formation. With regard to htt oxidation, aggregation was inhibited by
treatment with hydrogen peroxide (H2O2) in a dose dependent manner. Specifically, fibril
elongation and accumulation were prevented at high peroxide doses. The presence of
total brain lipid extract (TBLE) vesicles did not alter the observed inverse relationship
between htt aggregation and oxidant concentration. However, the combined effects of
lipid presence and H2O2 treatment caused larger reduction in fibrillization compared with
H2O2 treatment alone. Oxidation of htt-exon1 and/or lipid membranes altered aggregation
patterns directly on a bilayer surface. Oxidation of both the protein and lipid promoted the
appearance of plateau-like regions containing htt-exon1 aggregates. Collectively, these
results demonstrate that htt-lipid interactions play significant roles in modulating htt
aggregation pathways.
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1. Introduction:

Protein aggregation in Huntington’s and neurodegenerative

diseases
1.1 Neurodegenerative diseases and protein aggregation
A great number of neurodegenerative diseases are commonly characterized by
proteinaceous deposits comprised predominately of amyloid, broadly defined as protein
aggregates with a fibrillar morphology and a cross β-sheet secondary structure.1 These
diseases include Alzheimer’s, Parkinson’s, and Huntington’s Disease (HD). Similar to
protein folding, the formation and deposition of protein aggregates is a free energy driven
process (Fig. 1). Encoded in the amino acids sequence, nascent high enthalpy proteins
fold into enthalpically-favorable three-dimensional functional or native conformations via
folding intermediates that may prolong the folding process by acting as kinetic traps. 2 The
free energy landscape based on the various conformations available to a nascent protein
promotes a pathway toward the native protein structure. However, proteins can become
trapped in enthalpically unfavorable local energy minima, which represent misfolded
states along the rugged free energy landscape. Unlike the native state, misfolded proteins
associate to form aggregates due to increased intermolecular interactions between
exposed hydrophobic residues. The initial aggregates formed typically are small, transient
oligomeric species capable of reorganizing into more stable -sheet rich oligomers, or
highly structured, insoluble -sheet rich amyloid fibrils.3–5 Amyloid fibrils display enhanced
enthalpic stability due to a network of intermolecular hydrogen bonds holding the -sheets
together (Fig. 1). Alternatively, misfolded proteins can also form less compact amorphous
aggregates. These different aggregate species accumulate as the deposits, plaques, and

1

Figure 1. Energy landscape of protein folding and misfolding for amyloid-forming
proteins. Proteins fold into their energetically favorable native states based on a rugged
free energy landscape. The rugged energy landscape of protein folding also allow for
proteins to be trapped in local energy minima in a misfolded or partially folded state.
Misfolded proteins can proceed to form amorphous aggregates, or fibrils through
oligomers. Accumulation of aggregates form low energy plaques or inclusions.

2

inclusions in neurons that are associated with the emergence of neurodegenerative
diseases.
1.2 Proteins implicated in amyloid-based neurodegenerative diseases
Neurodegenerative diseases associated with amyloid formation share several
common features. Aggregate formation is a consequence of protein misfolding and is
triggered by conditions such as proteolysis, ageing, mutations, and other modifications.
However, specific proteins are implicated in different neurodegenerative diseases.
Table 1.1 Polyglutamine Disorders.
disease

common name

Huntington’s Disease (HD)

protein

polyQa

huntingtin

36-100

Spinobulbar
muscular Kennedy’s disease
androgen receptor
atrophy (SBMA)
Dentatorubral-pallidoluysian Haw River syndrome atrophin-1
atrophy (DRPLA)
Spinocerebellar ataxia type
ataxin-1
1 (SCA1)
Spinocerebellar ataxia type
ataxin-2
2 (SCA2)
Spinocerebellar ataxia type Machado-Joseph
ataxin-3
3 (SCA3)
Spinocerebellar ataxia type
CACNA1A
6 (SCA6)
Spinocerebellar ataxia type
ataxin-7
7 (SCA7)
Spinocerebellar ataxia type
PPP2R2B
12 (SCA12)
Spinocerebellar ataxia type
TATA-box
binding
17 (SCA17)
protein
aIndicates

38-65
49-88
39-88
33-77
55-86
21-33
38-120
66-78
47-63

the typical pathogenic polyQ range associated with each disease.

3

For example, neurofibrillary tangles of tau and extra-neuronal senile plaques of
amyloid- are hallmarks of Alzheimer’s Disease (AD); while Lewy bodies of α-synuclein
are observed in Parkinson’s Disease (PD). A subset of amyloid-based neurodegenerative
diseases is associated with expansion of a repeat glutamine (Q) stretch in specific
proteins that promote aggregation. To date, ten polyglutamine (polyQ) disorders have
been identified (table 1).6 There exists a variety of proteins associated with the different
polyQ disorders with implications for the specific neuronal populations impacted. For each
of the identified polyQ diseases, there exist a protein specific threshold of polyQ
elongation associated with pathogenesis (table 1). For all these diseases, expansion
beyond this critical threshold is correlated with disease severity and aggregation.
1.3 Huntingtin aggregation in Huntington’s Disease
HD is an inherited autosomal dominant disorder caused by expansion of a polyQ
domain near the N-terminus of the huntingtin protein (htt). Clinically, patients present with
a triad of movement disorder (chorea), psychiatric manifestation, and cognitive loss. 7
While the typical length of the polyQ stretch in htt is ~17-20 repeat units, the critical
threshold for HD is expansion beyond 35 repeat glutamine residues 8 (Table 1). The
expansion of the polyQ (polyQ length) also strongly correlates with the age of onset and
severity of the disease.8–10 For example, the average age of onset with a polyQ repeat
length of ~44 is about 35 years.11 In contrast, juvenile forms of HD (symptoms observed
before 20 years of age) have an average repeat length of ~60Q. 11
Htt is a large, multifunctional protein (~350 KDa, Fig. 2) typically found in the
cytoplasm. Htt has been associated with axonal trafficking of vesicles and organelles,
regulation of gene transcription, protein handling at the ER-Golgi complex, and
4

antiapoptotic activity.12 Of interest for HD is the first exon of htt (htt-exon1, Fig.2) and
other N-terminal fragments that contains the polyQ domain.13–15 Aggregates of N-terminal
fragments containing a polyQ expansion are found in the affected areas of the brain in
HD15 and are produced prior to pathogenesis through protease activities. 16,17 Proteolytic
products of htt form a variety of aggregate species.18,19

Figure 2. Huntingtin protein. Full length htt with 5 HEAT repeats (top). The inset at the
N-terminal of huntingtin is the first exon (htt-exon1) with three domains (bottom) namely:
Nt17 (N terminal amino acids), polyglutamine and polyproline.

The aggregation mechanism of huntingtin is similar to that of typical amyloid (Fig.
1 and 3). In a classical fibril formation pathway, fibril nucleation occurs either directly from
htt monomers or through oligomeric intermediates. While these pathways are not mutually
exclusive, polyQ length tend to shift the dynamics, with longer lengths favoring fibril
formation from monomeric htt.20–22 Additional complexity in aggregation derives from
competing aggregation mechanisms off-pathway to fibril formation that lead to amorphous
aggregates. While predominately comprised of fibrils, all aggregate types can be trapped
in larger inclusion bodies that are found ubiquitously in mouse models 23 and in the brains
of HD patients.24 The heterogeneity in the make-up of inclusions24 further suggests that
competing pathways lead to their formation. Regardless of the path taken, aggregates of
5

htt display toxic gain of function,25 as oligomers,26,27 fibrils,28,29 and inclusions30 have all
been linked directly to toxicity. Oligomers are present in brains of different HD disease
mouse models. Using a combination of Electron Microscopy and Atomic Force
Microscopy, analysis of the lysate obtained from the cortex of R6/2 mice revealed that
oligomers were present early, in 2-week-old mice.31 Similar globular aggregates were
obtained from 2 months old Hdh150 knock-in mouse models. Interestingly, these
aggregates are similar to those obtained in vitro, from htt-exon1 with 46 and 51 glutamine
repeats.31 The toxicity of fibrils have been demonstrated using various polyQ proteins. 28

Figure 3: PolyQ aggregation showing different pathways. (A) Nucleation of
monomeric htt to form fibrils. (B) Nt17 promotion of htt monomers aggregation into fibrils
via oligomeric intermediates. (C) Formation of annular and amorphous aggregates. (D)
Accumulation of various htt aggregates into inclusion bodies.
6

The fibrils obtained from different regions of an R6/2 mouse model displayed
various degrees of toxicity when transfected into neuro2a cells.32 Similarly, when httexon1 fibrils were introduced to SH-SY5Y cells, cell viability decreased significantly.29
Indeed, htt aggregation is crucial in HD, and polyQ expansion drives a variety of
aggregation pathways. However, beyond the polyQ, many other factors alter htt
aggregation.
1.4 Factors that modulate huntingtin aggregation
With toxicity directly associated with htt aggregation, understanding the complex
aggregation process, and the resulting heterogeneous mixture of aggregates species can
provide insight into the development of HD. However, the htt aggregation process is
highly dependent on various factors, including protein context and protein environment.
For example, protein context of an aggregation prone polyQ domain is thought to underlie
the variation in the critical polyQ expansion threshold observed across different polyQ
diseases.33–41 Specifically for htt, different N-terminal fractions of htt can lead to unique
aggregate species,42 and protein sequences directly flanking the polyQ domain strongly
influences polyQ aggregation.35,37,38,43–45 Similar to other amyloids, htt aggregation is also
influenced by its environmental conditions, i.e. pH, ionic strength, crowding, and
membranes.
1.4.1 Flanking sequences influence htt aggregation. Within htt-exon1, upstream of
the polyQ tract are the first 17 N-terminal amino acids (Nt17) that act as a lipid binding
motif39,46 and contains several post-translational modification (PTM) sites (Fig. 2).47,48 Cterminal to the polyQ is the proline-rich region, which contains two distinct polyproline
(polyP) tracts (Fig. 2). These polyQ flanking sequences (Nt17 and polyP) have contrasting
7

effects on htt aggregation. Nt17 promotes aggregation by facilitating oligomerization by
forming amphipathic α-helices that intermolecularly associate;33,35 polyP promotes
aggregation-incompetent monomeric species by extending a PPII-type helical structure
into the polyQ domain.49
The presence of polyP suppresses htt aggregation. 35,36,49–51 With a PPII helical
structure36,52 that extends into the polyQ tract in crystal structures,52 polyP hinders βsheet rich states of polyQ as revealed by molecular dynamics simulations. 36 Specifically,
addition of a C-terminal polyP sequence to synthetic polyQ peptides reduces aggregation
in vitro.49 In fact, the presence of the polyP in synthetic htt-exon1 mimic was sufficient to
alter the length of polyQ required for fibrillization.43,49 A similar observation has been
demonstrated in yeast cells38,51 where longer polyglutamine length is required to counter
the ability of polyP to hinder aggregation,51 and presence or absence of polyP is sufficient
to convert between benign and toxic aggregate species in yeasts. 38
Nt17 drives early steps in fibril formation35,39,53–57 through intermolecular
interactions. Structurally, Nt17 adopts multiple configurations in solution that vary from a
predominantly intrinsically disordered state as determined by nuclear magnetic
resonance (NMR),35 to a significantly α-helical structure revealed by circular
dichroism.35,58,59 This ability to adopt an amphipathic α-helical structure facilitates
intermolecular association to form α-helix rich oligomer intermediates.60 Specifically,
when oligomerization, which is often an early event in htt fibrillization, is promoted, the
polyQ domains of neighboring htt proteins come into close proximity, lowering the barrier
to nucleation.33,35,60 In contrast to polyP, this influence of Nt17 on aggregation of htt is not
dependent on its position. The insertion of Nt17 to either the N- or C-terminal of polyQ
8

resulted in increased aggregation.35 Indeed, the mechanism through which this binding
domain alters huntingtin aggregation lies in its ability and availability to interact with other
Nt17 domains. The removal of Nt17 from either htt-exon161 or its mimics35 resulted in
significant reduction in aggregation or a delayed monomer loss. In addition, through
interaction with other proteins, the Nt17 loses its ability to drive huntingtin aggregation.61,62
Nt17 may also be involved in intramolecular interactions with other regions of httexon1 to promote different conformations. Modulated by interactions with other proteins,
and with the polyQ acting as a hinge, intramolecular interactions between Nt17 and the
polyP regions of htt-exon1 is possible.63 Based on investigations using FRET, the nonpathogenic length polyQ domains provide the necessary flexibility for Nt17 and polyP to
interact; however, once polyQ domains reach the expansion threshold associated with
HD, the polyQ domain adopts a structure that prevents intramolecular association
between Nt17 and polyP. This observation has led to the “rusty hinge” hypothesis for htt
aggregation. This hypothesis states that the threshold associated with the disease arises
from the expanded polyQ domain’s lost flexibility, thereby freeing Nt17 from
intramolecular associations and promoting its ability to form intermolecular associations
that initiate aggregation. Based on its importance in initiating aggregation, Nt17 has
emerged as a therapeutic target.
1.4.2 Posttranslational modifications in Nt17 alter htt aggregation. Nt17 is a site for
several PTMs that impact htt function, localization, aggregation, and toxicity.64–68
Residues within Nt17 that are readily modified include lysine, threonine, serine and
methionine (Fig 4). PTMs within Nt17 include phosphorylation,65,69,70 acetylation,71
ubiquitination, SUMOylation66 and oxidation.72 Phosphorylation of Nt17 is associated with
9

reduced aggregation70,73 and toxicity.65,67,69,70 Phosphorylation likely inhibits fibrillization
by destabilizing the formation of the Nt17 -helix associated with initiating
aggregation.73,74

SUMOYlation of huntingtin modulates htt aggregation and toxicity by

blocking the formation of SDS insoluble aggregates in cells66 and in vitro.47 Acetylation
of lysine residues within Nt17 occurs in cells71 and in vitro.48 This modification inhibits
fibrillization of htt possibly by promoting the formation of unique oligomers that may be
incapable of transitioning into fibrils, or by stabilizing the oligomeric aggregates and
thereby delaying fibrillization.48

Figure 4: Nt17 helical wheel. The 17 amino acid residues of Nt17 and the first glutamine
of the polyQ domain showing the sites of various post translational modifications that are
possible within Nt17.

1.4.3 Oxidation of Nt17. Oxidative stress which is caused by imbalance of redox
states has been implicated in many neurodegenerative diseases. 75–77 Oxidation of htt,
10

especially within Nt17,72,78 is another PTM that alters htt aggregation. There are two
oxidizable methionine residues (M1 and M8) within Nt17 (Fig. 2 and 4). The oxidation of
M8 in htt-exon1 inhibits fibril formation.35,79,80 In an NMR study of htt-exon1 mimic
containing Nt17 and 10 glutamine repeats only, peroxide oxidation of M8 catalyzed by
titanium oxide nanoparticles stabilized aggregation-incompetent conformers by 4 folds.79
Precisely, the oxidation of the side chain of methionine to methionine sulfoxide prevented
the aggregation-induced broadening of NMR signal when compared with controls. In
contrast, without significant effect on the total amount of aggregates formed, postaggregation oxidation of M8 in htt-exon1 favored the occurrence of larger aggregates
through the accumulation of pre-oxidation formed aggregates.78
1.4.4 Interaction of huntingtin with membranes. Approximately half of htt present
in the cytoplasm is associated with lipid membranes, including the plasma membrane. 81
Htt localizes to a variety of membranous organelles causing their disruption and distortion
of their membranes, and ultimately their dysfunction. 82–87 Both full length and N-terminal
fragments

of

htt

interact

with

membranous

structures

such

as

ER, 58,88

mitochondria,82,83,89,90 the golgi apparatus,91 and the nuclear envelope.91 The interaction
of htt with membranous surfaces have pathological implications. For example, various
membranous structures are incorporated into inclusion bodies in cell lines expressing
mutant N-terminal fragments.92,93 In particular, the association of N-terminal fragments of
mutant htt with mitochondria is linked to mitochondrial dysfunction. 82,94–97 Mutant
huntingtin unfavorably alters mitochondrial membrane potential83 and promotes
mitochondrial fission.95
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Similar to disease severity and aggregation, the deleterious effect of mutant htt on
membranes are also polyQ length dependent.98–100 When vesicles made from various
phospholipids were probed for huntingtin interaction using brain cytosols obtained from
mice with wild type or mutant huntingtin, mutant htt associated more with
phospholipids.101 Similarly, AFM studies revealed that htt-exon1 disruption of bilayers
formed from total brain lipid extract (TBLE) was enhanced with increasing polyQ length. 99
In addition, exposure of htt-exon1 to TBLE bilayers altered the local mechanical
properties of the membrane.99 These studies further provide a hypothesis with regards to
the organelle dysfunction or impairment of membrane trafficking that is associated with
mutant htt,82 that is, htt containing expanded polyQ domains directly damage membranes
disrupting their normal function.
The direct interaction of N-terminal fragments of htt to lipid membranes is facilitated
by Nt17.37,102 This ability is regulated by PTMs. Lysine acetylation within Nt17 reduces
the affinity of htt-exon1 for lipid bilayers, reducing htt’s ability to damage membranes and
resulting in reduced cellular toxicity.48 Similarly, interaction of htt-exon1 with supported
TBLE was inhibited when htt exon1 was SUMOylated.47 Oxidation of Nt17 triggers release
of htt from the ER membrane, resulting in htt being trafficked to the nucleus. In vitro,
oxidation of methionine in a synthetic htt peptide reduced its binding to a 3:1 micellar mix
of lysophosphatidylcholine (LPC) and lysophosphatidylglycerol (LPG) by 3-4 folds,
probably due to increased repulsion between methionine sulfoxide and the lipid head
groups.80 Upon interaction with membranes, htt aggregation is altered; however, the
specific impact is dependent on membrane composition.81,98 Some lipid systems (POPC,
POPG, POPS, POPC/POPS) increased fibrilization;103–105 other lipid systems (TBLE,

12

POPE) inhibit aggregation.99,105–107 Nevertheless, unique aggregation mechanisms are
associated with htt aggregation on membrane surfaces. For example, POPC/POPS
membranes create high local htt concentrations, creating nucleation sites and promoting
aggregation.80,104 Both of these lipids also alter the -helical content of htt.58
1.5 Dissertation rationale and chapters summary
Aggregation of mutant huntingtin is associated with HD. The aggregation process
of mutant htt is greatly influenced by membrane association and chemical modifications.
In addition, mutant htt that are prone to aggregation are associated with organelle
dysfunction. Understanding the impact of cellular factors (i.e., organelle surfaces) and
chemical modifications on htt aggregation can reveal novel therapeutic approaches
toward treating HD. In Chapter 2, we investigated htt aggregation in the presence of
mitochondrial surfaces using a variety of systems. Mitochondrial surfaces suppressed
fibril formation and unique aggregation patterns directly on membranes. An important role
of cardiolipin, a lipid predominately found mitochondrial membranes, in suppressing htt
aggregation was revealed. In Chapter 3, the impact of htt oxidation, via H2O2 treatments,
on aggregation in the absence and presence of lipid membranes was determined.
Oxidation suppressed htt aggregation under both conditions. However, oxidation of lipids
also impacted the interaction between htt and membranes. Finally, Chapter 4 expands
upon these findings and how they can be applied to a better understanding of HD.
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2. Mitochondrial membranes modify mutant huntingtin aggregation
Huntington’s disease (HD) is a neurodegenerative disease caused by the
expansion of a polyglutamine (polyQ) tract near the N-terminus of the huntingtin (htt)
protein. Expanded polyQ tracts are prone to aggregate into oligomers and insoluble fibrils.
Mutant htt (mhtt) localizes to variety of organelles, including mitochondria. Specifically,
mitochondrial defects, morphological alteration, and dysfunction are observed in HD.
Mitochondrial lipids, cardiolipin (CL) in particular, are essential in mitochondria function
and have the potential to directly interact with htt, altering its aggregation. Here, the impact
of mitochondrial membranes on htt aggregation was investigated using a combination of
mitochondrial membrane mimics and tissue-derived mitochondrial-enriched fractions.
The impact of exposure of outer and inner mitochondrial membrane mimics (OMM and
IMM respectively) to mhtt was explored. OMM and IMM reduced mhtt fibrillization, with
IMM having a larger effect. The role of CL in mhtt aggregation was investigated using a
simple PC system with varying molar ratios of CL. Lower molar ratios of CL (<5%)
promoted fibrillization; however, increased CL content retarded fibrillization. As revealed
by in situ AFM, mhtt aggregation and associated membrane morphological changes at
the surface of OMM mimics was markedly different compared to IMM mimics. While
globular deposits of mhtt with few fibrillar aggregates were observed on OMM, plateaulike domains were observed on IMM. A similar impact on htt aggregation was observed
with

exposure

to purified

mitochondrial-enriched

fractions.

Collectively,

these

observations suggest mitochondrial membranes heavily influence htt aggregation with
implication for HD.
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Introduction: Mutant htt aggregates, localizes to organelles and promotes
organelle disruption
Huntington’s Disease (HD) is a progressive neurological disease caused by the
expansion of a polyglutamine (polyQ) track in the huntingtin protein (htt).1 PolyQ
expansions beyond a critical threshold (~35Q) promotes htt to aggregate into oligomers
and amyloid fibrils that eventually agglomerate to form inclusions within cells. 2 The extent
of aggregation,3,4 and toxicity5,6 is strongly correlated with polyQ length. The precise toxic
aggregate entities remain elusive. Rather than inclusions, many studies show that the
diffuse htt fraction correlates with cell death. 4,5,7 However, this diffuse fraction contains a
complex mixture of monomers, oligomers8,9 and fibrils.10 In addition, monomers,11
oligomers 12 and fibrils 13 all demonstrate toxic gain of function.
While expanded polyQ is central to htt aggregation, other factors, including peptide
sequences flanking polyQ14,15 and membranous surfaces,16 influence aggregation. The
first 17 amino acids (Nt17) of htt that directly precede polyQ enhances aggregation by
facilitating the formation of α-helix-rich oligomer intermediates.15,17 Nt17 functions as a
lipid binding domain by forming an amphipathic α-helix,18,19 and interactions between
Nt17 and lipids can promote distinct aggregation mechanisms.20 The ability of Nt17 to
bind membranes has been linked to htt trafficking.21,22 Htt is significantly associated with
membranous organelles, including mitochondria, endoplasmic reticulum (ER), the
nuclear envelope, tubulovesicles, endosomes, lysosomes, and synaptic vesicles.23–28 Htt
aggregates and inclusions accumulate brain lipids in mouse models.29–31 Htt aggregation
can damage lipid membranes32–35 and disrupt organelle integrity.27,28,36,37 Beyond being
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a target of aggregated htt, organelles provide subcellular environments that facilitate
aggregation by localizing and inducing structural changes in htt.38
A membranous organelle impacted by htt aggregates are the mitochondria. Wild
type htt and mutant htt (mhtt) fragments localize to mitochondria.24 However, mhtt
detrimentally impacts mitochondria trafficking,24 alters protein import,39 and bind other
mitochondrial proteins to promote mitophagy.40 Mitochondrial dysfunction in HD is further
demonstrated by increased lactate in the cortex and basal ganglia 41 and decreased
activities of complexes II and III of the electron-transport chain.42 Lymphoblast
mitochondria from HD patients and brain mitochondria from YAC transgenic mice
expressing mutant htt displayed lower membrane potentials and depolarized at lower
calcium loads.25 Importantly, htt directly interacts with mitochondria, as demonstrated by
subfractionation of mitochondria from knock-in mouse models.43 Specifically, mutant htt
associated with the outer mitochondrial membrane (OMM), increasing sensitivity to
calcium-induced permeabilization, i.e. membrane damage.43 mhtt also localizes to the
intermembrane where it is bound to an inner mitochondrial membrane (IMM) protein,
eliciting proteome imbalance.44 In addition, oligomers of htt are associated with
mitochondrial structural proteins, such as dynamin related protein (DRP1),45–47 and lead
to mitochondrial fragmentation, abnormal mitochondrial dynamics, and oxidative DNA
damage.26,45,48
Despite mitochondrial dysfunction being established in HD, little is known
concerning how the presence of mitochondrial surfaces influence htt aggregation. Here,
the aggregation of htt-exon1 with 46 glutamine repeats (htt-exon1(46Q)) was evaluated
in the presence of purified mitochondria, which suppressed fibril formation and altered
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oligomer morphology. To distinguish the role of the OMM and IMM, the aggregation and
membrane activity of htt-exon1(46Q) in the presence of vesicles that mimicked the
composition of these membranes was investigated. From these studies, a prominent role
for cardiolipin (CL) was revealed.
2.2 Methods
2.2.1 Purification of GST-htt exon1 fusion protein: Gluthathione S-transferase
(GST)-htt-exon1(46Q) fusion proteins was expressed in Escherichia coli after induction
with isopropyl thiogalactopyranoside (IPTG) for 4 h at 30 °C and purified as previously
described.49 Briefly, after expression, the cells were lysed by a combination of lysozyme
and probe sonication. The resulting mixture was purified using affinity liquid
chromatography (Bio-Rad LPLC, GST-affinity column). Relevant protein fractions and
purity were determined by SDS-PAGE. Prior to every experiment, GST-htt-exon1(46Q)
fusion proteins were subjected to high spin centrifugation (22,000×g, 4 oC, 30 min) to
remove pre-existing aggregates, and protein concentration was measured with a Bradford
assay. Cleavage of GST was facilitated by incubation with factor Xa (New England
Biolabs). All experiments were carried out in an aggregation buffer [50 mM Tris-HCl (pH
7) and 150 mM NaCl].
2.2.2 Isolation of Mitochondrial-Enriched Fractions: Mitochondria-enriched
fractions (MEFs) were isolated separately from bovine liver or murine brain using a
Mitochondria Isolation Kit for Tissue (ThermoFisher, Catalog # 89801). In short, tissues
were cut to sizes less than 200 mg, washed with PBS before being homogenized with a
dismembrator. The homogenized tissue was centrifuged (1000×g, 3 min, 4 oC), the
supernatant discarded, and the pellet retained. Then, the pellet was resuspended in
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BSA/Mitochondria Isolation reagent A. The suspension was vortexed for 5 s and allowed
to rest on ice for 2 min before the addition of Mitochondria Isolation reagent B. Prior to
addition of Mitochondria isolation reagent C, the suspension was periodically agitated and
centrifuged at high speed for 5 min. To remove the supernatant, mitochondria were
pelleted by centrifugation (700×g, 10 min, 4 oC). The pellet was washed, centrifuged at
12000×g to remove residual supernatant before being stored at -80 oC until use.
Enrichment of mitochondria was evaluated by an ELISA assay for cytochrome C
(Cytochrome C ELISA Kit, Abcam) and Western blot analysis. Prior to each experiment,
mitochondria pellets were thawed on ice, and the mitochondria concentration was
determined by measuring total protein content using a Bradford Assay.
2.2.3 Preparation of Lipid Vesicles: All lipids (PC, PE, PI, PS and CL) were
purchased from Avanti Polar Lipids (Alabaster, AL) and stored at -20 oC until use.
Respectively, these lipids were dissolved in chloroform and mixed to achieve appropriate
molar ratios (53:27:9:7:4 for OMM,50,51 45:25:9:6:15 for IMM50 and a third mimic, IMM –
CL, which was made by maintaining the molar ratio of IMM but without CL. In addition,
mixtures with the following CL:PC molar ratios: (1) 0:100, (2) 3: 97 (3) 5: 95 (4) 11:89 and
(5) 18:82 were made. Chloroform was removed using an Eppendorf Vacufuge. All dried
lipid films were reconstituted to 1 mg/ml in the aggregation buffer, subjected to 10
freeze/thaw cycles, and bath sonicated for 30 mins to obtain lipid vesicles.
2.2.4 Thioflavin-T Fluorescence Assay: Htt-exon1(46Q), lipid vesicles and
thioflavin T (ThT, Sigma-Aldrich, St. Louis, MO) were adjusted to a final concentration of
20 M, 0.15mg/ml and 0.05 mg/ml respectively. Using a SpectraMax M2 and black Costar
96-well clear flat bottom plates set to 37 oC, ThT fluorescence kinetics was monitored for
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18 h at 440 nm excitation and 484 nm emission. Fibril disaggregation ThT experiments
were performed by mixing preformed fibrils (30 M, 8 h) with neat buffer, lipid vesicles,
and ThT to achieve a final htt-exon1 concentrations of 10 M (fibrils), and ThT
concentration of 0.05 mg/ml. Lipid vesicles final concentrations were varied between 7.5
mg/ml and 22.5 mg/ml to achieved protein to lipid concentrations of 1:10, 1:20 and 1:30.
Experiments were carried out at 37 oC and monitored for 24 h.
2.2.5 Atomic Force Microscopy (AFM): AFM experiments were performed with a
Nanoscope V Multimode atomic force microscope (Veeco, Santa Barbara, CA) equipped
with a closed-loop vertical engage J-scanner. For ex situ AFM, incubations of httexon1(46Q) (20 μM) with and without the various lipid vesicles (0.15 mg/ml or ~ 200 μM)
or MEFs (1.4 mg/ml BSA equivalent) were maintained at 37 oC. Aliquots of the incubations
drawn at various time points were deposited on freshly cleaved mica (Ted Pella Inc.,
Redding, CA) and allowed to rest for 75 s. The mica was then washed with 200 μL of
ultrapure water and dried with a gentle stream of air. Dried samples were measured by
ex situ AFM with oxide-sharpened silicon cantilever with a nominal spring constant of 40
N/m and resonance frequency of ~300 kHz.
For in situ AFM experiments, a fluid cell equipped with a silicon nitride cantilever
with a 0.1 N/m nominal spring constant was used. The drive frequency ranged between
7.5-9.5 kHz, and scan rate was maintained between 1.5 - 2 Hz. Initially, background scans
of freshly cleaved mica under neat buffer (20 µL) were taken to ensure the cleanliness of
the fluid cell. Next, an equal volume of the prepared OMM or IMM vesicles were
introduced to a final concentration of 0.5 mg/ml within the fluid cell. Bilayer formation on
mica via vesicle fusion was observed by continuous imaging. Once sufficient bilayer
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formed, htt-exon1(46Q) was injected to achieve a final protein concentration of 10 M
and lipid concentration of 0.25 mg/ml in the fluid cell. After protein injection, images were
collected continuously for 60 – 120 min. For both ex situ and in situ AFM experiments,
images were processed and analyzed with Matlab equipped with the image processing
toolbox (MathWorks, Natick, MA) as previously described.52
2.2.6 Filter Retardation and Dot Blot Assay: Incubations of Isolated mitochondria
(1.4 mg/ml BSA equivalent) with and without 20 M htt exon1(46Q) were maintained at
37 oC. After 1, 3, 5 and 8 h of incubation, 3 L aliquots were drawn from each incubation
and boiled in 610 L of 0.5% sodium dodecyl sulfate (SDS) loading buffer for 5 min. Boiled
samples were cooled to room temperature and serially diluted with Tris Buffered saline
(TBS, 25 mM Tris) to achieve successive halved concentrations of 1.2 g, 0.6 g and 0.3
g of htt exon1(46Q). Similar volumes were drawn from the test sample (htt +
mitochondria) and negative control. A slot blot manifold (GE Healthcare) with pre-wet
nitrocellulose membrane (NCM, 0.45 m pore size, GE Healthcare) was assembled and
connected to vacuum. 300 L of each serial dilution was loaded into the slots of the
manifold. After all loaded sample were pulled through the membrane by vacuum, the
membrane was carefully removed, dried at room temperature, and soaked overnight in
blocking buffer (5% milk solution in TBS) at 4 oC. Blocked membranes were incubated on
an orbital shaker for 1 h with htt-specific monoclonal primary antibody, MW8 (specific for
the C-terminal stretch of htt-exon1, detects fibrils, Developmental Studies Hybridoma
Bank, University of Iowa, 1:350 dilution) or with voltage-dependent anion channel (VDAC)
Polyclonal Antibody (Thermo Fisher Scientific, catalog # PA1-954A, RRID AB_2304154).
After washing with TBS, membranes were incubated on an orbital shaker for 1 h with the
31

secondary Goat anti-mouse or Goat anti-rabbit alkaline phosphatase antibody (1:1000
dilution). For color development, the membrane was dried at room temperature and
incubated in BCIP/NBT substrate for 10 min. Dot blots were performed by depositing
aliquots of samples after 0, 1, 3, 5, and 8 h of incubation directly onto NCM. Membranes
were blocked in milk solution before incubation in soluble huntingtin specific monoclonal
primary antibody, MW1 (specific for the polyQ stretch, detects monomeric htt,
Developmental Studies Hybridoma Bank, University of Iowa, 1:350 dilution). The
membrane was then incubated in secondary antibody and developed as described for
filter retardation assay.
For disaggregation experiments, htt-exon1(46Q) was incubated at 30 M for 8 h.
Incubations of htt-exon1(46Q) was mixed with neat buffer and with and without
mitochondrial enriched fractions (final concentration 1.4 mg/ml) or with and without lipid
vesicles (final concentration 0.15 mg/ml, or htt:lipid 1:10). Incubations were maintained at
37 oC for 8 h. Aliquots were taken after 1 and 8 h and boiled in SDS, deposited on NCM
probed with MW8 and developed as described above.
2.2.7 Monomer loss assays: Incubations of MEFs (1.4mg/ml BSA equivalent) with
and without 20 µM htt-exon1(46Q) were incubated at 37°C. In addition, an incubation of
20 µM htt-exon1(46Q) without MEFs was used as a control. Aliquots were taken from
these incubations at various time points (0, 1, 3, and 5 h) and centrifuged at 20000×g for
40 min. The concentration of the resulting supernatant was determined with a Bradford
assay performed on a NanoDrop spectrophotometer (Thermo Fisher Scientific). To
determine the concentration of mitochondria-bound htt, concentration of incubations of
htt and mitochondria were corrected for mitochondrial backgrounds of control
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experiments. Supernatants were also evaluated with a dot blot assay performed as
described above.
2.3 Results
2.3.1 Mitochondrial membrane mimics reduce htt fibril formation. All experiments
in this study were performed with a mutant htt fragment that expresses exon1 with 46Q
(htt-exon1(46Q)), which was purified from Escherichia coli as a soluble fusion with
glutathione S-transferase (GST). After purification, aggregation is initiated by addition of
factor Xa, which cleaves GST. With the knowledge that lipids influence htt
aggregation,20,34,35,53 it is plausible that the distinct membranes of mitochondria influence
aggregation. The OMM and IMM are mostly composed of similar lipids but of varying

Figure 2.1. Raw ThT signals associated with the different lipid vesicles used to study htt
aggregation reported in Figures 2.2A, 2.3 and 2.5A. Error bars represent SEM and are
provided every 0.5 h.
abundance. Therefore, two distinct lipid vesicles systems were used to mimic the OMM
(PC:53%, PE:27%, PI:9%, PS:7%, CL:4%)50,51 and IMM (PC:45%, PE:25%, PI:9%,
PS:6%, CL:15%)50 to determine their impact on htt-exon1(46Q) aggregation. Htt-
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exon1(46Q) was incubated (20 µM, 37°C) alone and with mitochondria mimics (OMM and
IMM) at a molar protein to lipid ratio of 1:10. Aggregation was monitored using a ThT

Figure 2.2. Mitochondrial membrane mimics inhibit fibril formation. (A) ThT analysis of
the aggregation of htt-exon1(46Q) in the presence or absence of mitochondrial
membrane mimics OMM, IMM, and IMM without CL (lipid to protein molar ratio of 10:1).
Error bars represent SEM and are provided every 0.5 h (B) Representative AFM Images
of htt exon 1(46Q) incubated with and without IMM and OMM. (C) Analysis of the surface
area covered by fibrils as a function of time. Error bars represent SEM. * represents p
<0.05 and ** represents p < 0.01. (D) Correlation plots of average diameter vs height of
all oligomeric aggregates of htt exon1(46Q) (blue), htt exon1(46Q) + OMM (red), and httexon1(46Q) + IMM (green). For each correlation plot, the height (top) and diameter (right)
histograms are provided.
assay, which fluoresces when bound to -sheet rich fibrils. While the raw signal shifts with
OMM and IMM vesicles without htt, the ThT fluorescent background associated with
vesicles is stable (Fig. 2.1), demonstrating that the addition of lipid does not interfere with
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the assay. Both mitochondria membrane mimics reduced fibrillization with IMM having
the larger impact (Fig. 2.2A). The impact of OMM and IMM on aggregation was dependent
on the lipid to protein ratio, as increased lipid concentration inhibited fibrillization more
strongly (Fig. 2.3). Although the mimics are similar in lipids composition, CL content was
the largest variable with IMM having significantly more CL. Therefore, additional ThT
assays were performed with the addition of vesicles comprised of the same ratios of lipids
as IMM but without any CL. With CL excluded from the lipid vesicles, the inhibitory effect
of the mimics was lost (Fig. 2.2A).

Figure 2.3. Dose dependent impact of (A) OMM and (B) IMM vesicles on httexon1(46Q) (10 µM) aggregation as assessed by ThT assays. Error bars represent
SEM and are provided every 0.5 h.

To further evaluate the impact of mitochondrial membranes on htt aggregation, httexon1(46Q) was incubated (37°C) at 20 µM in the absence or presence of OMM or IMM
mimicking vesicles at a molar peptide to lipid ratio of 1:10. These incubations were
sampled at 1, 3, 5, and 8 h for AFM analysis. Control incubations of lipid vesicles alone
were also deposited on mica to determine lipid backgrounds (Fig. 2.4). The extent of fibril
formation in the presence of the different lipid vesicle systems was evaluated by AFM
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image analysis using custom scripts written in Matlab. These scripts identify individual
aggregates in images and measure a variety of morphological features. To distinguish
fibrils from oligomers, it was determined that fibrils and fibril bundles occupied more than
9,000 nm2 on the mica surface. Using that criteria as a filter, the relative area of the
surface covered by fibrils was determined for all conditions. The analysis was normalized
to the maximum fibril content associated with the htt-exon1(46Q) control at 8 h. Within 1
h, htt-exon1(46Q) fibrils were observed in the control, and the number and size of fibrils
increased with time (Fig. 2.2B-C). By 5 and 8 h, larger fibrils with entangled morphologies
were present.

Figure 2.4. Control ex situ AFM images of backgrounds associated with the lipid
systems deposited on mica and used to study htt aggregation. The blue lines
correspond to the height profiles directly below each image.
While small fibrils formed within 1 h in the presence of mitochondrial membrane mimics,
both IMM and OMM significantly reduced fibril coverage (Fig. 2.2B-C). Consistent with
the ThT assay, the inhibitory effect of IMM was larger compared with OMM.

Next, htt oligomer morphology formed in the presence of OMM and IMM mimics
was analyzed. For this, oligomers were defined as being at least 1.0 nm in height with an
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occupied area of 500 to 9,000 nm2 and an aspect ratio (longest distance across to
shortest distance across) of less than 3.0, indicating a globular structure. Htt-exon1(46Q)
oligomers formed in the presence of OMM vesicles were morphologically similar to
oligomers formed in the absence of lipid (Fig.2.2D). That is, there was substantial overlap
in correlation plot of diameter vs height and histograms. Oligomer formed in the absence
and presence of OMM vesicles typically displayed mode heights of ~4.5-6 nm at each
time point (Fig. 2.2D). However, htt oligomers formed in the presence of IMM vesicles
were initially distinguishable from control after 1 h of incubation as a significant population
of taller aggregates was observed (mode height of ~6-9 nm). These taller oligomers
persisted after 3 h of incubation, but were less pronounced at later time points. At both
the 1 and 3 h time points, the height distribution of htt oligomers formed in the presence
of IMM were significantly different (p < 0.05) to those observed for htt incubated alone
and with OMM. Due to the larger heights of oligomers formed in the presence of IMM
vesicles at 1 and 3 h, these appear as a distinct population across the bottom of the
correlation plot.
2.3.2 Cardiolipin impacts htt aggregation. As changes in htt aggregation in the
presence of mitochondrial membrane mimics correlated with CL content, a simplified
system was used to further clarify the role of CL. Using a ThT assay, htt-exon1(46Q)
aggregation was

37

Figure 2.5. Cardiolipin impacts htt aggregation. (A) ThT analysis of the aggregation of
htt-exon1(46Q) in the presence of PC vesicles with varying amounts of CL. Error bars
represent SEM and are provided every 0.5 h (B) Representative AFM images of htt exon
1(46Q) incubated alone, with PC vesicles, or with PC vesicles with 18% CL. (C) Analysis
of the surface area covered by fibrils as a function of time. Error bars represent SEM. *
represents p <0.05 and ** represents p < 0.01. (D) Correlation plots of average diameter
vs height of all oligomeric aggregates of htt-exon1(46Q) (blue), htt exon1(46Q) + PC (red),
and htt exon1(46Q) + PC/18% CL (green). For each correlation plot, the height (top) and
diameter (right) histograms are provided.

monitored in the presence of POPC vesicles that contained various amounts of CL (318% by moles) at a peptide lipid ratio of 1:10 (Fig. 2.5A). Background controls (vesicles
alone) were also performed (Fig. 2.1). With pure POPC vesicles, the extent of fibril
formation was slightly reduced (15-20% after 14 h) compared with control (no lipid
vesicles). Initial increases in CL content (up to 5%) enhanced fibrillization by ~15-20%.
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Further increasing CL content resulted in inhibition of fibril formation, as 11% and 18 %
CL content reduced the ThT signal by ~40%, and ~80% respectively.
Next, htt-exon1(46Q) was incubated (20 µM, 37°C) with POPC vesicles or POPC
vesicles with 18% exogenous CL and sampled for AFM analysis (Fig. 2.5B-C) as was
performed with IMM and OMM vesicles. Htt-exon1(46Q) was incubated in the absence of
lipid as a control. A few small fibrils were observed after 1 h for all three incubations;
however, the presence of POPC and POPC + 18% CL vesicles significantly reduced fibril
formation with time. Vesicles containing CL reduce the fibril load on mica to a larger extent
(Fig. 2.5B-C). Morphological features of oligomers from these incubations with POPC or
POPC + 18% CL were similar to control (Fig. 2.5D). However, oligomers formed in the
presence of POPC + 18% CL vesicles displayed larger variation in their morphology at
different time points. At 1 h, htt oligomers associated with POPC + 18% CL had a smaller,
tighter distribution of size compared to the other incubations. At 3 h, oligomers associated
with POPC + 18% CL had a clear proportion of taller oligomers that appeared in the
correlation plots in a similar fashion to oligomers formed in the presence of IMM mimic
vesicles (Fig. 2.2D), which had comparable CL content. This is the only time point at
which these oligomers were statistically different (p < 0.05) in size compared with control.
After this 3 h time point, oligomers formed in the presence of POPC + 18% CL were
indistinguishable from control.
2.3.3 Htt aggregation varies on the surface of OMM and IMM membrane mimics.
While OMM and IMM membranes impacted htt aggregation as demonstrated by ThT and
ex situ AFM analysis, both techniques monitor bulk aggregation within an incubation. That
is, they do not distinguish between htt aggregation occurring on a membrane surface or
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in solution. As it has been reported that htt aggregation occurs via a unique mechanism
on POPC/POPS lipid surfaces,20 in situ AFM was employed to directly observe httexon1(46Q) on supported OMM and IMM mimicking bilayers (Fig. 2.6). OMM or IMM
mimic vesicles were directly injected into an AFM fluid cell, and the formation of a
supported lipid bilayer by vesicle fusion on mica was observed via continuous imaging.
While OMM vesicles readily formed a complete bilayer, IMM did not, as several holes
remained in IMM supported membranes after several hours of imaging. While we typically
confirm complete bilayer formation before exposure to proteins in this type of in situ AFM
studies,34,35,54,55 these incomplete supported IMM mimic bilayers were exposed to httexon1(46Q). However, reference images and membrane mapping were utilized to avoid
analyzing areas of the membrane that contained holes prior to protein injection. With that
caveat stated, supported bilayers were exposed to htt-exon1(46Q) (final concentration of
10 µM in the fluid cell), and the bilayers were continuously imaged to directly observe
aggregation and morphological changes occurring at the bilayer surface.
Upon exposure to htt, small oligomers quickly developed on the OMM surface
(within 6 minutes, Fig. 2.6A). Around these oligomers, granular regions of increases
surface roughness developed. While not extensive, some fibrils developed within these
granular regions. These fibrils were often highly branched and grew in length with time.
Some oligomers appeared to transition into fibrils after prolonged exposure to OMM. With
that said, the vast majority of aggregates observed on OMM appeared globular. Over
time, these structures started to swell (both in height and area) leading to increased
roughness of the membrane. These rough patches did not develop over the entire OMM
surface even after 87 min of exposure to htt-exon1(46Q). That is, regions of unperturbed

40

OMM bilayer persisted. An unperturbed OMM bilayer had an RMS roughness of 0.673
nm. The granular regions were significantly rougher, and this roughness steadily
increased with time, reaching 7.045 nm within 120 minutes (Fig. 2.6B).

Figure 2.6. Huntingtin aggregation varies on the surfaces of OMM and IMM membrane
mimics. (A) Time-resolved in situ AFM images of supported bilayers of OMM and IMM
exposed to 10 M htt-exon1(46Q). Blue arrows indicated the same spot on sequential
images. Green arrows indicate fibrils growing in sequential images. Purple arrows
indicate oligomers. Red arrows indicate plateau-like regions developing on the IMM
bilayer. Black circles highlight a region of the IMM bilayer that developed holes that
spanned the entire membrane. Analysis of the RMS of disrupted regions of the surface
of (B) OMM and (C) IMM bilayers before (0 min) and after (7 to 120 min) exposure to 10
M htt-exon1(46Q). Error bars represent SEM.

Morphological changes on the IMM bilayer upon exposure to htt-exon1(46Q) were
markedly different (Fig. 2.6A and Fig. 2.7). Despite the difficulties of forming a complete
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bilayer prior to htt exposure, the holes in the IMM bilayer were quickly filled when htt was
injected into the fluid cell, and these filled holes were associated with plateau-like domains
that rose above the initial bilayer (~3.838 nm in height) surface and spread to a broader
area than the initial hole. While these plateau-like domains formed on regions of the IMM
bilayer that contained an established hole prior to exposure to htt, these domains formed
even in areas that did not initially contain any holes. These morphological changes on
IMM bilayers developed more rapidly compared to those observed on OMM bilayers. That
is, these plateau-like regions quickly enveloped the surface. Between the plateau-like
domains, relatively smooth bilayer was observed for the first few minutes, however, these
spaces quickly roughened with a granular morphology, often resulting in the development
of large bilayer defects that extend all the way through the bilayer, exposing mica.
Interestingly, discrete htt aggregates, oligomers, or fibrils, were typically not observed on
the IMM membrane. A freshly prepared IMM mimic supported bilayer had an RMS
roughness of 0.420 nm, but upon exposure this significantly increased (Fig. 2.6B). The
RMS roughness changes caused by exposure to htt-exon1(46Q) was typically larger on
IMM compared to OMM at similar time points. However, due to the aggressive
morphological changes observed on IMM, extending experiment on IMM beyond ~60 min
was not feasible. Taken together, htt aggregation proceeds via distinct pathways on either
OMM or IMM, resulting in distinct morphological changes of the bilayers.
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Figure 2.7. Additional in situ AFM images of supported (A) OMM and (B) IMM bilayers
exposed to 10 µM htt-exon1(46Q). The blue lines correspond to the height profiles
directly below each image.
2.3.4 OMM, IMM, and CL containing vesicles do not destabilize preformed htt
fibrils. It has been reported that some lipid systems can destabilize amyloid fibrils, causing
them to refold into monomers or other aggregate species.56,57 More specifically, CL can
refold α-synuclein fibrils.58 With this in mind, the ability of OMM, IMM, POPC, and POPC
+ 18% CL vesicles to destabilize htt fibrils was investigated (Fig. 2.8). Htt-exon1(46Q)
was incubated at 30 µM for 8 h to allow for the formation of fibrils. The presence of fibrils
was confirmed by AFM. Then, these fibrils were diluted (final concentration of 20 µM) with
neat buffer, OMM, IMM, POPC, or POPC +18% CL vesicles with htt to lipid ratios of 1:10,
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1:20, and 1:30. The stability of these fibrils was tracked for 24 h with ThT fluorescence
normalized to the control htt fibrils diluted in neat buffer (Fig. 2.8A). At all htt to lipid ratios,
each lipid system was unable to destabilize fibrils as the relative ThT signals remained
constant. To further validate that fibrils were stable in the presence of these lipid systems,
the incubations were also sampled after 1 and 8 h for analysis by a filter trap assay and
AFM (Fig. 2.8B-C). Serial dilutions (1.2, 0.6, 0.3 µg htt) of each incubation were boiled in
SDS before being drawn through a NCM membrane (0.45 µm pore size) under vacuum,
trapping large, SDS insoluble fibrils.

Figure 2.8. OMM, IMM, and CL do not disaggregate preformed htt fibrils. (A) Preformed
fibrils were incubated alone and with lipid vesicles of OMM, IMM, POPC, or POPC +
18%CL, and fibril stability was monitored by ThT fluorescence over 24 h. Peptide to lipid
ratio ranged from 1:10 to 1:30. (B) Filter trap assay to determine preformed fibril stability
after 1 and 8 h of incubation in buffer or after exposure to vesicles of IMM, OMM, POPC,
and POPC + 18% CL. Each condition was serially diluted and probed with the anti-htt
antibody MW8. (C) AFM images of preformed fibrils alone and in the presence of POPC
and POPC + 18%CL vesicles.
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The membrane was probed with anti-htt antibody MW8 that targets the C-terminal
residues of htt-exon1 and readily detects fibrils.59,60 Fibrils were readily detected with
similar intensities by the filter trap for all conditions and time points. Additionally, similar
amounts of fibrils were detected in AFM images, confirming that IMM, IMM, POPC, and
POPC vesicles containing CL do not readily destabilize htt fibrils for at least 24 h.
2.3.5 Mitochondrial-enriched fractions inhibit fibril formation. With OMM and IMM
mimic vesicles and bilayers heavily influencing htt aggregation, the impact of tissuederived (from murine brain or bovine liver) mitochondrial-enriched fractions (MEFs) on htt
aggregation was investigated. While the isolated mitochondria were often non-functional,
these fractions consisted predominately of mitochondrial lipids and proteins. To determine
how the presence of these mitochondria components impact htt aggregation, httexon1(46Q) was incubated (20 µM, 37°C) in the presence and absence of these MEFs.
Control incubations of MEFs without htt were also carried out. The MEF concentration
was approximated by measuring total protein content of each purification, and all
experiments were performed at 1.4 mg/ml mitochondrial protein content. Aliquots were
taken from these incubations and deposited on mica after 1, 3, 5, and 8 h of incubation
for AFM analysis. Initially, htt-exon1(46Q) incubations contained a variety of small
oligomers, but after 3 h of incubation short fibrils appeared (Fig. 2.9A). At 5 and 8 h, fibrils
were more abundant and longer. Fibrils were not observed from incubation of httexon1(46Q) mixed with MEFs derived from murine brain over 5 h of incubation. After 8 h,
only a few short fibrils appeared, but abundant oligomer-like features were observed at
all time points (Fig. 2.9A). However, control incubations of murine brain derived MEFs
alone also contained features reminiscent of htt oligomers (Fig. 2.9A).
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Figure 2.9. The impact of MEFs derived from murine brains on htt-exon1(46Q)
aggregation. (A) Representative ex situ AFM images from incubations of htt-exon1(46Q)
(20 µM) with and without MEFs at various time points. Control images of MEFs alone are
also presented. Due to large height differences between htt aggregates and mitochondria,
the blue boxes in each image indicate areas using the colormap labeled with blue font.
Examples of fibrils (green arrows), oligomers (purple arrows), and mitochondria (blue
arrows) are marked. (B) Area of fibrils covered by htt-exon1(46Q) and htt-exon1(46Q) +
MEFs in (A) reported relative to the maximum area covered by fibrils formed by httexon1(46Q) at 8 h. (C) Filter trap assay investigating aggregation of htt-exon1(46Q) in
the presence and absence of MEFs. Serial dilutions (1.2, 0.6 and 0.3 µg of htt
exon1(46Q)) for the htt alone and with MEFs, as well as the volume equivalents of the
MEF alone control, were deposited on NCM (0.45 µm pore size) and probed with the antihtt antibody MW8. (D) Densitometry analysis of the slot blot assay in (C) taken across
three independent experiments and normalized to the 1.2 µg htt alone sample at 8 h. (E)
Dot blot of the same experimental systems investigated in (C) were performed. 2 L
aliquots of each incubation were deposited on NCM (0.1 m pore size) and probed with
the anti-htt antibody MW1 to detect monomeric mutant htt. (F) Densitometry analysis of
the dot blot assay in (E) taken across three independent experiments and normalized to
the 0 h time point for htt and htt + MEF samples respectively. (G & H) Determination of
monomer remaining in the supernatent after centrifugation of 20 µM htt-exon(46Q) with
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and without MEFs by (G) a Bradford assay and (H) dot blot analysis. Tthe dashed red line
in (G) at 0.8 mg/mL indicates the initial concentration of GST-htt fusion protien in the
incubation. The time points represent when the monomer concentration was measured.
The monomer concentration of the htt + MEFs samples were corrrected for residual
protein backgrounds associated with MEFs. The dot blots in (H) were probed with MW1.
All error bars represent standard error. * represents p < 0.05, and ** represents p < 0.01.
Morphological differences between these oligomer-like features observed in MEF alone
controls and those observed in htt-exon1(46Q) incubated with MEFs will be analyzed
later. In incubations of MEFs with and without htt, large mitochondria were observed by
AFM at each time point. A similar pattern of aggregation was observed for incubation
experiments performed with bovine liver derived MEFs (Fig. 2.10A). That is, httexon1(46Q) alone readily formed fibrils, but in the presence of MEFs, fibrils were not
observed at any time point. To quantify this observation, all AFM images were analyzed,
as previously described for studies with lipid vesicles, to determine the fibril load on mica
for each condition. In this analysis, both mitochondria and fibrils met the larger than 9,000
nm2 criteria. As a result, the identified (by the Matlab script) structures were visually
inspected to distinguish fibrils from mitochondrial features. The analysis of fibril load was
normalized to the maximum fibril content associated with the htt-exon1(46Q) aggregation
control at 8 h, as it contained the largest fibril content (Fig. 2.9B, Fig. 2.10B). Whether
incubated with brain or liver derived MEFs, the fibril load on mica was significantly
reduced at all time points. It is possible that the presence of htt-exon1(46Q) could damage
mitochondria presented in the MEF. As the mitochondria present in the MEFs were not
consistently functional, the number and size of mitochondria observed in AFM images
was evaluated to determine if this was impacted by exposure to htt. However, no
significant changes were observed between mitochondria incubated in the presence or
absence of htt-exon1(46Q) (Fig. 2.11).
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Figure 2.10. The impact of MEFs derived from bovine liver on htt-exon1(46Q)
aggregation. (A) Representative ex situ AFM images of aliquots of htt-exon1(46Q) (20
µM) with and without MEFs taken after 8 h of incubation. An image of control incubations
of MEFs incubated alone is also presented. Due to the large height differences between
htt aggregates and mitochondria, the blue boxes in each image indicate areas using the
colormap labeled with blue font. (B) Analysis of the area covered by fibrils. These values
are normalized to the fibril coverage in the htt alone sample at 8 h. Black arrows indicate
that no fibrils were identified. (C) Filter trap assay investigating aggregation of httexon1(46Q) in the presence and absence of MEFs at various time points and probed with
the anti-htt antibody MW8.
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Figure 2.11. Analysis of identifiable mitochondria populations incubated with (orange)
and without (red) htt-exon1(46Q). Mitochondria in AFM images taken at various time
points were identified with automated scripts written in Matlab. These scripts generated
AFM images with identifed mitochondria labeled, allowing for visual verification.
Features reatained for this analysis were taller than 7.5 nm and occupited a surface
area of 0.08 µm2.
While AFM experiments suggested that the presence of MEFs inhibited fibril
formation, there was the possibility that the presence of MEFs may interfere with fibrils
adhering to the mica surface. As a result, a filter trap assay was performed to validate the
AFM results. To probe for fibril formation, aliquots were taken from the different
incubations, boiled in SDS, and serially diluted, (1.2, 0.6, 0.3 g htt or the volume
equivalent for the MEF alone control) and probed via a filter trap assay using the anti-htt
antibody MW8. For htt-exon1(46Q) incubated alone, no fibrils were trapped at 0 h;
however consistent with the AFM assay, significant htt was detected after 3, 5, and 8 h of
incubation, and this was slightly reduced with serial dilution of the aliquot (Fig. 2.9C-D).
When htt-exon1(46Q) was incubated with murine brain-derived MEFs, a significant
amount of htt was detected by the filter trap at each time point for the non-diluted aliquot,
but unlike htt alone, htt content significantly decreased upon serial dilution. With control
mitochondria, no htt was detected as expected. At first glance, this assay suggests htt
formed fibrils in the presence of MEFs; however, an alternative interpretation seems
plausible. Mitochondria are large enough to not pass through the filter trap. Exogenous
htt bound to mitochondria would be concentrated on the organelle surface and detectable
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by this assay. In comparison to free floating htt fibrils, serial dilution would impact the
amount of htt detected in the presence of mitochondria due to concentrating effect of the
organelle surface. As a result, htt observed with mitochondria is not necessarily fibrillar
but is bound to the organelle. However, boiling with SDS should breakdown intact
mitochondria in the MEF, allowing them to pass. To determine if mitochondria were being
retained by the filter trap assay, membranes were stained using a primary antibody for
VDAC, a mitochondrial protein (Fig. 2.12). If mitochondria are completely broken down
by boiling in SDS, VDAC would pass through the filter. However, VDAC would be detected
if mitochondria are retained in the filter trap. Based on this test, mitochondria were
retained by the filter trap, and this retention was reduced via serial dilution.

Figure 2.12. Immunochemical analysis of murine brain derived MEFs with and without
htt-exon1(46Q) at various time points. Serial dilutions (2.0, 1.0 and 0.5 µg) of 1.4 mg/ml
MEF (BSA equivalents) which are of comparable volumes to 1.2, 0.6 and 0.3 µg of 20 µM
htt exon1(46Q)) were boiled in SDS and deposited on NCM ((0.45 µm pore size) at
various time points and probed with VDAC polyclonal antibody.
To further clarify if fibrils formed in the presence of MEFs, a dot blot assay was
performed. Small aliquots of the different incubation conditions were deposited on NCM
(0.1 µm pore size) and probed with the anti-htt antibody MW1, which targets polyQ but
can’t detect the compact amyloid core of fibrils.59 This allows for detecting non-fibrillar
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forms of htt. For incubations of htt-exon1(46Q) alone, significant, non-fibrillar htt was
detected at 1 h (Fig. 2.9E-F); however, detectable htt dramatically decreased with time
as fibrils formed. When htt-exon1(46Q) was incubated with murine brain derived MEFs,
similar htt staining was observed at each time point, confirming suppression of fibril
formation. Similar patterns were observed in both filter trap and dot blot assays performed
with bovine liver-derived MEFs (Fig. 2.13).

Figure 2.13. Immunochemical analysis of htt-exon1(46Q) without and with bovine liverderived MEFs at various time points. (A) Filter trap assay investigating htt aggregation of
htt-exon1(46Q) in the presence and absence of MEFs. Serial dilutions (1.2, 0.6 and 0.3
µg htt exon1(46Q)) and the volume equivalents of htt exon1(46Q) + MEFs and MEFs
alone were deposited on NCM (0.45 µm pore size) at various time points and probed with
the anti-htt antibody MW8. (B) To detect non-fibrillar aggregates, complementary dot blots
of the same experimental systems investigated in (A) were performed (B). 2 L aliquots
of each incubation were deposited on NCM (0.1 m pore size) and probed with the antihtt antibody MW1 to detect monomeric htt.
As the filter trap assay suggested htt was binding to mitochondria, a variation of a
standard monomer loss assay was performed to assess the extent to which htt localized
to the mitochondria present in the MEF (Fig. 2.9G). Htt-exon1(46Q) was incubated (20
µM or 0.84 mg/mL of GST-htt fusion protein, 37°C) in the presence and absence of freshly
isolated murine-derived MEFs. MEFs were also incubated without htt-exon1(46Q) as a
control. After 0, 1, 3, and 5 h of incubations, aliquots were removed and centrifuged at
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20,000×g for 40 minutes to pellet aggregated htt and mitochondria present in the MEFs.
The supernatant was collected, and protein concentration determined by a Bradford
assay. As a result of this procedure, the supernatant concentration was measured ~1 h
after sampling the incubations, and these adjusted times are reported on Fig. 2.9G (1, 2,
4, and 6 h). In addition, the protein concentration of the htt-exon1(46Q) + MEFs
incubations were corrected for residual protein associated with mitochondria alone
controls. At 1 h, a significant and similar amount of monomer loss was observed for httexon1(46Q) incubated with and without MEFs compared to the initial htt concentration.
However, by 4 and 6 h, the monomer loss associated with htt-exon1(46Q) incubated in
the absence of MEFs continued to decrease, consistent with extensive aggregation.
When incubated with mitochondria, the monomer concentration stabilized at later time
points, suggesting that the monomer loss was due to htt pelleting with mitochondria and
that aggregation was suppressed. While corrected with control experiments, residual
mitochondria protein content was still a complication. As a result, a second method to
measure htt-exon1(46Q) concentration in the supernatant was employed for validation.
The collected supernatants were evaluated with a dot blot assay using MW1 to
specifically measure htt content (Fig. 2.9H). The detectable htt-exon1(46Q) in the
supernatant decreased with time in a manner consistent with fibrillization. With MEFs, the
htt-exon1(46Q) detected in the supernatant was stable across all time points.
The Bradford assay measured free protein content (~0.55 ± 0.06 mg/mL across all
time points) in the supernatants of the control mitochondria alone incubation even though
mitochondria pellet under the centrifugal conditions were used. To determine if residual
contents in the supernatant of these MEF samples underlie the observed reduction in htt
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fibrillization, ThT assays were performed with 20 µM htt-exon1(46Q) in the presence and
absence of supernatant from centrifuged (20,000×g for 40 minutes) MEFs derived from
both murine brain and bovine liver (Fig. 2.14). The volume of supernatant added to these
ThT assays was equivalent to the volume that would have been required to achieve the
1.4 mg/ml mitochondrial protein content prior to centrifugation. Neither of the
supernatants significantly altered the ThT signal, confirming that the entity reducing
fibrillization was present in the pellet.

Figure 2.14. Control ThT assay demonstrating the impact of residual material in the
supernatant of centrifuged MEFs on htt-exon1(46Q) (20 µM) fibril formation.
Supernatant from both murine brain-derived and bovine liver-derived MEFs were tested
and obtained after centrifgation for 40 min at 20,000 ×g. Error bars represent SEM.

2.3.6 Mitochondria influence htt oligomer formation. Having observed fibril
suppression by MEFs, we returned to the AFM images to determine if there were any
morphological differences associated with oligomers formed in the presence of these
fractions. Oligomer morphology was analyzed using the same criteria employed to study
incubations with lipid vesicles described above. Correlation plots of diameter and height
were constructed, as well as histograms for both dimensions (Fig. 2.15). Complicating
this analysis is that a great number of features in the MEFs alone met these criteria. While
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there was some overlap in the correlation plots for these MEF-related features with
oligomers of htt-exon1(46Q) observed in control (no MEFs), the background features
associated with mitochondria (in the absence of htt) from both murine brain and bovine
liver had smaller observed heights (mode typically in the range of 2-3.5 nm, Fig. 2.15 and
Fig. 2.16). In general, many htt oligomers were morphologically distinct from MEF
backgrounds as visualized in the correlation plots. With this stated, oligomers of httexon1(46Q) in the absence of MEFs were distinguishable from those formed in the
presence of MEFs due to differences predominately in height. That is oligomers formed
by htt alone at early time points had mode heights of ~4-5.5 nm that could shift to larger
sizes by 8 h (~6-7 nm), but oligomers formed in the presence of MEFs had mode heights
of 7-11 nm after 1, 3, and 5 h of incubation. These oligomers of htt in the presence of
MEFs became smaller at 8 h (mode height of ~5-7 nm). In that regard, htt oligomers
formed in the presence of MEFs were significantly larger than htt oligomers formed in the
absence of MEFs (p < 0.05, students T-test) for all time points except after 8 h of
incubation. These differences in oligomer morphology were more pronounced with bovine
liver-derived fractions (Fig. 2.15), with oligomers formed in the presence of these MEFs
having significantly larger height distributions (p < 0.05) compared to htt controls after 3
and 5 h of incubation. Importantly, the correlation plots make it clear that these features
are not the same as those observed in the MEF alone controls (background), and features
similar to those observed in the control are not observed when mitochondria are
incubated with htt. For example, the height distributions of measured features of samples
with htt-exon1(46Q) (in the presence and absence of brain- or liver-derived MEFs) were
typically significantly (p < 0.05) larger than the background features observed in images
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of mitochondria alone samples. The only exception is the 8 h time point with brain derived
mitochondria. This suggests that the background debris associated with MEFs is
accumulating with htt, resulting in distinct globular aggregates. Due to this difference in
heights, oligomers formed in the presence of MEFs appear as a distinct population across
the bottom of the correlation plots, similar to those observed in some time points with IMM
and PC + 18%CL vesicles described earlier.

Figure 2.15. Murine-derived brain MEFs alter oligomer morphology. Correlation plots of
average diameter vs height of all oligomer-sized aggregates of htt exon1(46Q) (blue), htt
exon1(46Q) + MEFs (green), and MEFs alone (red). For each correlation plot, the height
(top) and diameter (right) histograms are also provided.

2.3.7 Mitochondria-enriched fractions do not destabilize preformed htt fibrils. As
with the pure lipid systems, the ability of MEFs to destabilize htt fibrils was determined.
As MEFs interfered with ThT assays, this ability was only assessed by filter trap assays
using MW8 and AFM (Fig. 2.17). Preformed htt-exon1(46Q) fibrils were diluted (final
concentration of 20 µM) with neat buffer or MEFs (mitochondrial protein content
equivalent of 1.4 mg/ml).
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Figure 2.16. Analysis of oligomers formed by htt-exon1(46Q) in the presence and
absence of MEFs derived from bovine liver. Correlation plots of average diameter vs
height of all oligomer-sized aggregates of htt-exon1(46Q) (blue), htt-exon1(46Q) + MEFs
(green), and MEFs (red). For each correlation plot, the height (top) and diameter (right)
histograms are also provided.
Serial dilutions (1.2, 0.6, 0.3 µg htt) of each condition were prepared for the filter trap
assay after 1 and 8 h of incubation. Fibrils were readily detected with similar intensities
by the filter trap for the fibril control and fibrils + MEFs incubations at both time points. A
control MEF alone did not elicit any response in the filter trap assay. Additionally, AFM
images confirmed the stability of preformed htt fibrils exposed to MEFs. Similar to
mitochondria incubated with fresh, unaggregated htt, there was no apparent alteration in
mitochondria morphology upon exposure to preformed htt fibrils.
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Figure 2.17. MEFs do not destabilize preformed htt fibrils. (A) Preformed fibrils were
incubated alone and with MEFs, and fibril stability was monitored by a filter trap assay
after 1 and 8 h. Each condition was serially diluted and probed with the anti-htt antibody
MW8. (B) AFM images of preformed fibrils alone and in the presence of MEFs. Due to
large height differences between htt aggregates and mitochondria, the blue boxes in each
image indicate areas using the colormap labeled with blue font.

2.4 Discussion
Amyloid

formation

is

implicated

as

a

common

factor

across

many

neurodegenerative diseases, including HD, Alzheimer’s disease (AD), and Parkinson’s
disease (PD). The aggregation processes associated with amyloids are dependent on a
variety of cellular factors, including the presence of lipid membranes.16 Beyond
influencing aggregation, membranes represent potential targets for amyloid induced
damage and disruption. In HD, htt-induced membrane damage may underlie observed
dysfunction of membranous organelles.27,28,36,43 Here, the direct impact of model
mitochondrial membranes and MEFs on htt aggregation was determined. To glean the
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role of mitochondrial membranes on htt aggregation, htt aggregation was monitored in
the presence of OMM or IMM mimics, and membrane mimics impeded fibril formation
with IMM having the larger impact. In addition, IMM mimics promoted a unique htt
oligomer at early time points. The influence of the mitochondrial membrane mimics
appeared to be CL content dependent, and removing CL from the IMM mimic
compromised its ability to impede fibril formation. Therefore, the role of CL in htt
aggregation was systematically determined, and two regimes were observed. Simple
membranes with low CL content slightly promoted htt fibrillization; whereas, higher, more
physiologically relevant CL content inhibited fibrilization. Htt aggregation was also directly
observed on the surface of OMM and IMM mimic bilayers. Exposure to htt altered
membrane morphology differently between these two lipid systems. Discrete oligomers
and some fibrils formed on OMM that were associated with granular regions of membrane
disruption. Discrete aggregates did not readily appear on IMM, but the membrane
developed distinct regions displaying a plateau-like morphology. In between these
plateaus, the membrane roughened, and holes spanning the entire bilayer appeared. The
presence of MEFs inhibited htt fibril formation in a similar fashion to the mimic systems
and also promoted the formation of a distinct htt oligomer. However, neither the purified
lipid systems nor the MEFs destabilized preformed htt fibrils. Collectively, these results
highlight the complexity of htt-exon1 aggregation in the presence of mitochondria and that
the two distinct membranes of mitochondria impact htt aggregation in unique ways with
CL playing a prominent role.
Full length htt is a large, ~350 kDa protein; however, this study utilized a htt-exon1
fragment with an expanded polyQ domain as a model system. Use of exon1 as a model
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system is physiologically justified and is extensively used. Expression of mutant htt-exon1
in rodent and primate models captures aggregation patterns and elicits neurological
defects similar to HD.61–63 Indeed, a variety of N-terminal htt fragments are produced in
HD brains.61–64 These cleavage products are produced by caspase, calpain and other
protease activity, which precedes pathogenesis.65,66 N-terminal fragments appear to be
more potently cytotoxic and aggregation prone, compared to full-length htt.67–69
Importantly, N-terminal fragments (including exon1) of mutant htt associate with
mitochondria, resulting in dysfunction.
While mitochondria inhibited htt fibrillization and promoted unique oligomeric
species, simplified model systems implicated CL as playing a major role in these
phenomena. The impact of CL-containing membranes on htt aggregation was dependent
on CL content. With low CL content (<5%), htt fibrilization was slightly accelerated, but
when CL content was high (>5%), fibril formation was inhibited in a dose dependent
manner. Recently, molecular dynamic simulations of ternary lipid systems demonstrated
a similar CL-content dependent impact on membrane fluidity 70. That is, membrane fluidity
was reduced at low CL content (2-10%); whereas, 15% CL content greatly increased
fluidity.70 This suggests that the varied impact of CL on physicochemical properties of
membranes, such as fluidity, influence the varied interaction of htt with membranes
observed here. While the influence of lipid membranes on htt aggregation has been well
appreciated,71 the htt/lipid interaction is a complicated phenomenon that is highly
dependent on lipid content. The impact of a variety of model lipid systems on htt
aggregation has been explored, ranging from pure lipid systems 20,72,73 to brain lipid
extracts. For example, POPC/POPS lipid vesicles accelerate fibril formation,20 but total
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brain lipid extract (TBLE) inhibits fibrillization.72 Altering the composition of TBLE with
cholesterol, sphingomyelin, or GM1 further modifies htt aggregation.34,35 In particular,
exogenous cholesterol promoted the formation of plateau-like domains34 similar to those
observed on IMM mimic bilayers.
CL is a phospholipid that is unique in both shape and location, that is, it is almost
exclusively found in the mitochondria with higher abundance in the IMM. CL is comprised
of one anionic head and four lipid tails. The disparity between the sizes of the head and
tails of CL causes it to adopt a conical shape inducing bilayer curvature. The distinctive
properties of this lipid contribute to its role in maintaining IMM and OMM integrity and as
a regulator of mitochondria dynamics,74–76 either through formation of microdomains77 or
recruitment of other proteins.51 The permeabilization of mitochondrial membranes by
amyloid-forming proteins, e.g. α-synuclein and the β-amyloid peptide, is associated with
other neurodegenerative diseases and appears mediated by CL content.50 In particular,
CL promotes ion pore formation by α-synuclein78

and recruits α-synuclein to

mitochondrial surfaces causing fragmentation.79 Htt obtained from mouse brain lysates
have a particularly high affinity for CL,80 which may in part be due to htt’s ability to
preferentially bind curved membranes81 which are promoted by CL.82,83 In addition, the
lipid binding domain, Nt17, has a net positive charge that may further stabilize binding
with negatively charged CL headgroups, as the ability of Nt17 to bind lipids is sensitive to
electrostatic interactions.73
With htt aggregating to different extents in the presence of and producing unique
morphological changes in IMM and OMM model systems, the extent of exposure of these
membranes in intact mitochondria to htt is an important consideration. The interaction of
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htt with the OMM is well established, and htt remains attached to the OMM even during
mitochondrial isolation.24,43,84–86 The ability of htt to reach the intermembrane space and
reach the IMM remains unresolved. By probing immunoblots with anti-htt antibodies of
mitochondrial subfractions, htt was found to be associated with both the IMM and OMM;
however, a complete separation between these two membranes may not be possible with
this method.43 In the same study, analysis of susceptibility to trypsin digest suggested
that htt was not internalized into mitochondria and is associated with the cytosolic face of
the OMM in a conformation that is partially resistant to trypsin proteolysis. Additional
reports using varying combinations of limited trypsin digest, selective OMM
permeabilization, and alkali treatment provide conflicting evidence with regard to the
ability of htt to enter the intermembrane space. In support of htt reaching the IMM, mutant
htt appears to specifically binds to subunits of the mitochondrial inner membrane
translocase subunit TIM23,39,44 which would require htt crossing the OMM. With regard
to these TIM23 studies, trypsin proteolysis assays coupled with selective permeabilization
of the OMM suggested htt localization into the intermembrane space of mitochondria.44
However, recent reports using similar assays did not detect htt in the intermembrane
space.87 Due to our inability to verify mitochondrial functionality in our MEFs, it is likely
that the integrity of the OMM was compromised. As a result, our study does not provide
additional data with regard to this controversy. Rather, we demonstrate that the presence
of mitochondrial surfaces alters htt aggregation and that this is predominately impacted
by CL content. While the CL content is appreciably smaller in the OMM than the IMM, CL
content can be enriched in the OMM during mitophagy.88,89
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The lipid composition of the IMM and OMM facilitate many functions of
mitochondria.90 These phospholipids provide structural integrity, and mitochondrial
proteins are located and function within these membranes.90 Wild type and mutant htt
fragments localize to mitochondria, but only mutant htt negatively impacts mitochondria
trafficking24 and protein import.39 In HD, the ability of mitochondria to maintain calcium
homeostasis is significantly impaired,25 which could be caused by htt directly damaging
mitochondrial membranes as observed here on OMM and IMM mimics. Beyond lipids,
there are several htt/mitochondrial protein interactions that play a role in HD. Htt binds
proteins that target mitochondria to promote mitophagy40 or fragmentation.45 A prominent
mitochondrial fission protein, dynamin related protein (DRP1) is overexpressed in HD
models, altering mitochondrial dynamics in HD.45–47 CL, which is implicated here in
modifying htt aggregation, also stimulates DRP1 activity.91,92 Mutant htt also localizes to
the intermembrane space of mitochondria, binding an IMM protein (TIM23) and eliciting
proteome imbalance.44
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3. Oxidation promotes distinct huntingtin aggregates in the presence and absence
of membranes
Huntington’s disease is a fatal neurological disorder caused by expanded
polyglutamine (polyQ) domain within the first exon (exon1) of huntingtin (htt) protein.
PolyQ expansion leads to the formation of a variety of aggregates including globular
oligomers, -sheet rich fibrils and other amorphous species. Htt aggregation is also
influenced by the preceding 17 N-terminal amino acids (Nt17) of htt-exon1. Nt17 also
modulates the binding of htt to membranes by forming amphipathic -helix. Many amino
acids within Nt17 are susceptible to posttranslational modifications (PTMs), including the
two methionine residues that are prone to oxidation. We investigated the impact of
oxidation within Nt17 on htt aggregation both in the presence and absence of lipid
membranes made from total brain lipid extract (TBLE). We studied this using two
experimental systems: htt-exon1 mimic peptide (N17-Q35-P10) and full length htt-exon1
with 46 glutamine repeats (htt-exon1(46Q)). N17-Q35-P10 exposed to hydrogen peroxide
(H2O2) treatment showed reduced fibril formation in an oxidant-dose dependent manner
as revealed by Thioflavin T (ThT) assay. Similarly, htt-exon1(46Q) also showed
progressive reduction in fibrillization with increasing H2O2 as assessed by Atomic Force
Microscopy (AFM). Specifically, shorter fibrils and more oligomers were formed at high
oxidant concentrations. Upon addition of lipid vesicles, fibrillization was generally
hindered in both experimental systems even before the addition of H2O2. Combined
effects of H2O2 treatment and lipid presence showed similar trend as was observed in the
absence of lipids. That is, oligomerization was promoted at the expense of fibril
elongation. In addition, the aggregation of both oxidized and unoxidized htt-exon1 was
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monitored on supported lipid bilayers by in situ AFM. The supported lipid bilayers were
formed from both oxidized and unoxidized TBLE. In both systems without H2O2, that is,
pre-oxidized and unoxidized bilayers, granular htt aggregates that grew with time were
formed. However, in the presence of H2O2, htt granular aggregates accumulated on the
bilayer in distinct plateau-like regions. Collectively, these observations suggest that
oxidation of methionine residues within Nt17 plays a crucial role in both the aggregation
of htt and its ability to bind lipid membranes.
3.1 Introduction: Nt17 has posttranslational modification sites and modulates htt
aggregation and organelles interaction
Huntington’s disease is a genetic neurological disorder caused by elongation of a
polyglutamine (polyQ) stretch within the huntingtin (htt) protein.1 PolyQ expansion beyond
a critical threshold (~35) triggers htt aggregation into proteinaceous inclusions within
cells.2 Beyond inclusions, htt forms a variety of other aggregate species, ranging from
small oligomers to -sheet-rich fibrils.3–6 As a consequence, htt aggregation results in a
heterogeneous mixture of distinct aggregates. While much effort has been targeted to
elucidating specific toxic aggregates, toxic gain of function has been attributed to
oligomers, fibrils, and inclusions.7–12 In particular, htt aggregates damage membranous
structures throughout the cell, including the ER,12,13 mitochondria,14,15 and nuclear
membranes.16 As a result, understanding the aggregation process and the resulting
complex mixture of aggregates may be key in unraveling multifaceted toxic profile of HD.
Beyond expansion, amino acid sequences directly flanking the polyQ domain
influence aggregation.17–19 The first 17 N-terminal residues (Nt17) that directly precede the
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polyQ domain promote fibrillization via oligomeric intermediates 17,20. This is facilitated by
Nt17’s ability to form an amphipathic -helix that facilitates the formation of oligomers.20,21
Nt17 peptides form a variety of dimers, trimers, and tetramers that arrange in an antiparallel manner.22,23 The resulting α-helix-rich oligomers bring polyQ domains from
different htt proteins together to accelerate the nucleation process. 17,20,24
Approximately half of htt present in the cytoplasm is associated with
membranes.25–27 The ability of Nt17 to form an amphipathic α-helix also facilitates httexon’s ability to bind lipid membranes.21,28 Nt17 is involved in targeting htt to the
autophagic vacuoles, and ER, mitochondrial, and Golgi membranes.29,30 A variety of toxic
processes may encompass htt/lipid interactions. Htt association with organelle
membranes is linked with disrupted trafficking,31 synaptic degeneration,32 and neuronal
cell death.33 Lipid membranes are also susceptible to htt-induced disruption and
permeabilization.14,34–36 The direct interaction facilitated by Nt17 of htt-exon1 with
intracellular and subcellular membranes further adds to the complexity of the aggregation
process. Lipid membrane can either increase37 or decrease38 fibrillization, depending on
the physicochemical properties of the bilayer based on lipid composition.39–41
Both the ability of Nt17 to promote htt aggregation and bind lipid membranes is
modulated by post translational modifications (PTMs) within Nt17.42,43 Interestingly, Nt17
can undergo a variety of post-translational modifications (PTMs), including oxidation,44
phosphorylation,45,46 acetylation,47 SUMOylation48 and ubiquitination.49 Many of these
PTMs impact oligomer and fibril formation,42,43,50 potentially by altering the stability of the
α-helix-rich oligomeric intermediates. Oxidative stress is caused by an imbalance
between the production of reactive oxidative species (ROS) and antioxidant cellular
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defenses. At high ROS levels, htt localization is shifted from cytoplasmic membranes
such as the ER towards nuclear entry,44 suggesting that oxidation alters the affinity of
Nt17 for the ER. In this regard, the Nt17 may function as a ROS sensor, as it contains
two methionine residues (M1 and M8) susceptible to oxidation.44 Methionine (M8) plays a
crucial role in stabilizing the Nt17 helical conformation, and modification of this residue
triggers htt -ER release, resulting in cellular toxicity without the formation of larger htt
aggregates.30 Similarly, other studies have observed reduced or inhibited19,51,52
aggregation of htt-exon1 mimicking peptides that were oxidized.
Here, we investigate how oxidative environments, produced by H2O2, influence httexon1 aggregation in the presence and absence of model total brain lipid extract (TBLE)
lipid bilayers. TBLE was chosen as the model lipid system as it is comprised of a
physiologically relevant ratio of lipids, i.e., acidic and neutral phospholipids, gangliosides,
cholesterol, sphingolipids, and isoprenoids. In the absence of lipid, exposure to hydrogen
peroxide suppressed htt fibrillization in a dose-dependent manner. This fibril suppression
was accompanied with an increase in the oligomer population accompanied by a slight
shift to larger oligomers. With the introduction of TBLE vesicles, htt aggregation was
further reduced. Oxidation modified htt-induced morphological changes on the surface of
the TBLE bilayers.
3.2 Methods
3.2.1 Preparation of synthetic peptides. A synthetic htt-exon1 mimic peptide
(Anaspec) consisting of Nt17, a polyQ stretch of 35 residues, and a polyproline stretch of
10 residues (referred to as Nt17-Q35-P10) was solubilized based on previously described
protocols.53 The peptide was initially treated with a 1:1 mixture of Hexafluoroisopropanol
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(HFIP) and Trifluoroacetic acid (TFA). The solvent was then removed under vacuum in a
vacufuge (Eppendorf). The resulting dried films were stored at -20°C until needed. Prior
to any experiment, the peptide film was reconstituted in dimethyl sulfoxide (DMSO) to a
concentration of 4000 µM. The DMSO stock solution was then diluted 200× in aggregation
buffer [50 mM Tris-HCl (pH 7) and 150 mM NaCl] to achieve a final peptide concentration
of 20 µM with 0.5% DMSO.
3.2.2

Purification

of

GST-htt

exon1

fusion

protein:

Gluthathione

S-

transferase(GST)-htt-exon1(46Q) fusion proteins was expressed in Escherichia coli
purified

as

previously

described.3

Briefly,

after

induction

with

isopropyl

thiogalactopyranoside (IPTG) for 4 h at 30 °C, the cells were lysed by a combination of
lysozyme and probe sonication. The GST-htt fusion protein was purified from the lysate
using affinity liquid chromatography (Bio-Rad LPLC, GST-affinity column). Relevant
protein fractions and purity were determined by SDS-PAGE. Prior to every experiment,
GST-htt-exon1(46Q) fusion proteins were subjected to high spin centrifugation
(22,000×g, 4oC, 30 min) to remove pre-existing aggregates, and protein concentration
was measured with a Bradford assay. Cleavage of GST was facilitated by incubation with
factor Xa for 90 min on ice (New England Biolabs). All experiments were carried out in
aggregation buffer [50 mM Tris-HCl (pH 7) and 150 mM NaCl].
3.2.3 Preparation of lipid vesicles: Lipid vesicles were prepared as previously
described54 with some modifications. Total brain lipid extract (TBLE; Avanti Polar Lipids,
Alabaster, AL) were dissolved in chloroform, aliquoted into smaller samples, placed in a
vaccufuge to remove the choloroform, and the dried films were stored at -20°C until
needed. For experiments using pre-oxidized lipid, TBLE samples were oxidized by
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hydrating the lipid films with 300L of 3% (w/v) H2O2, incubated in a Thermomixer at 60
oC

and 1400 rpm for 3 h, aliquoted into smaller samples, dried in a vacufuge, and stored

at -20 °C. Unoxidized and oxidized TBLE films were reconstituted in the aggregation
buffer to obtain 1 mg/ml solutions with vigorous mixing at 60 oC for 30 min. Lipid vesicles
were made by subjecting films to 10 freeze-thaw cycles followed by bath sonication for 1
h. ThT and incubation experiments were carried out by adding 30 L of the lipid stock
solution to protein samples (synthetic peptide or htt-exon1(46Q)) to achieve a final
concentration of 0.3 mg/mL of lipid and 20 M protein.
3.2.4 Thioflavin T (ThT) assay: Monitoring fibril formation was achieved with

thioflavin T (ThT; Sigma-Aldrich, St. Louis, MO) assays.ThT ssays were carried
out in a Costar 96-well black clear flat bottom plate.using a SpectraMax M2 plate
reader. All experiments were performed at, 37 oC for 10 h with reading every 5 min. The
excitation wavelength was 440 nm, and the emission wavelength was 484 nm. All
conditions were performed in triplicate on any give plate, and a minimum of three
independent plates were run for all experiments. The final concentration of the Nt17-Q35P10 peptide was 20 µM in all wells, and the final concentrations of H 2O2 were 0.02, 0.1,
0.25, 0.5, 10 or 20 mM to achieve the 1x, 5x,12.5x, 25x, 500x, and 1000x relative to the
peptide concentration conditions. Similar assays were performed in the presence of TBLE
vesicles (0.3 mg/ml final concentration). The ThT concentration per well was 60 µM.
3.2.5 Polydiacetylene (PDA) Vesicle Binding Assay: 10,12-Tricosadiynoic acid
(GFS Chemicals, Columbus, OH) and TBLE dissolved at a 2:3 molar ratio in a 1:4
ethanol/chloroform solution. The solution was evaporated off under a stream of N 2, and
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the resulting film was dissolved with aggregation buffer at 70 °C. The solution was
sonicated for 10 min intervals at 100 W using a sonic dismembrator (FisherSci) to achieve
an opaque solution that was stored overnight at 4 °C to allow for the formation of mixed
vesicles. The PDA was then polymerized by irradiation at 254 nm for 10 min at room
temperature with constant stirring. Polymerization resulted in a blue solution. The
colorimetric response was monitored by ultraviolet–visible (UV–vis) spectroscopy to
quantify the binding of htt-exon1(46Q) to vesicles with a SpectraMax M2 microplate
reader (Molecular Devices) in a 96-well plate format. Each plate contained negative
controls (neat buffer A) and a positive control (final concentration of 100 μM NaOH). The
NaOH control was used to standardize PDA results across experiments.55 Readings were
taken every 5 min for 18 h at 25 °C by measuring the blue absorbance (640 nm, Ablue)
and the red absorbance (500 nm, Ared). The % colorimetric response (%CR) was then
determined by the following equation:

%𝐶𝑅 =

𝑃𝐵0 −𝑃𝐵1
𝑃𝐵0

× 100

(1)

where PB is defined as Ablue/(Ablue + Ared). PB0 is determined from the negative control,
and PB1 is obtained from each experimental condition.56,57
3.2.6 Atomic Force Microscopy (AFM): AFM experiments were performed with a
Nanoscope V Multimode atomic force microscope (Veeco, Santa Barbara, CA) equipped
with a closed-loop vertical engage J-scanner. For ex situ AFM, incubations of httexon1(46Q) (20 μM) were mixed with H2O2 to achieved various ratios of htt-exon1(46Q):
H2O2 1:5 or 5x, (1:50 or 50x, 1:200 or 200x and 1:1000 or 1000x). A duplicate of each
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system was also mixed with TBLE vesicles to a final lipid concentration of (0.30 mg/ml or
~ 400 μM). A third system involves the mixing of unoxidized htt-exon1(46Q) with oxidized
TBLE vesicles. All systems were maintained at 37 oC and aliquots of the incubations
drawn at various time points were deposited on freshly cleaved mica (Ted Pella Inc.,
Redding, CA) and allowed to rest for 75 s. The mica was then washed with 200 μL of
ultrapure water and dried with a gentle stream of air. Dried samples were measured by
ex situ AFM with oxide-sharpened silicon cantilever with a nominal spring constant of 40
N/m and resonance frequency of ~300 kHz.
For in situ AFM experiments, a fluid cell equipped with a silicon nitride cantilever
(nominal spring constant of 0.1 N/m) was used. The drive frequency ranged between 7.59.5 kHz, and scan rate was maintained between 1.5 - 2 Hz. Initially, background scans of
freshly cleaved mica under neat buffer (20 µL) were taken to ensure the cleanliness of
the fluid cell. Next, an equal volume of the prepared 1 mg/ml of TBLE or pre-oxidized
TBLE vesicles were introduced to a final concentration of 0.5 mg/ml within the fluid cell.
Bilayer formation on mica via vesicle fusion was observed by continuous imaging. Once
sufficient bilayer formed, cleaved htt-exon1(46Q) (or htt-exon1(46Q) that had been
cleaved and incubated with 1000x H2O2 on ice) was injected to achieve a final protein
concentration of 10 M and lipid concentration of 0.25 mg/ml in the fluid cell. After protein
injection, images were collected continuously for up to 160 min. For both ex situ and in
situ AFM experiments, images were processed and analyzed with a combination of
WSxM58 and Matlab equipped with the image processing toolbox (MathWorks, Natick,
MA) as previously described.59
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3.3 Results
3.3.1 Oxidation suppresses htt fibrilization. To establish if the presence of H2O2
would alter htt aggregation, the rate of fibril formation of a synthetic htt-mimic peptide
containing Nt17, a 35 residue long polyQ domain, and a 10 residue polyP domain
(Nt17Q35P10) was investigated (Fig. 3.1). 20 M of Nt17Q35P10 was exposed to various
concentrations of H2O2 to achieve peptide:H2O2 ratios ranging from 1:1 to 1:1000.

Figure 3.1: The impact of H2O2 on Nt17Q35P10 aggregation as assessed by a ThT
assay. Nt17Q35P10 was incubated at 20 M without H2O2 (control) and with H2O2 at molar
ratios of 1x, 5x, 12.5x, 25x, 500x, and 1000x that of the peptide.

Aggregation was monitored using a ThT assay, which detects -sheet formation
associated with fibrils.60 Based on this assay, treatment with H2O2 reduced fibril formation
in a dose dependent manner (Fig. 3.1). With as little as 1x H 2O2, the ThT signal was
significantly reduced by ~25%. Increasing the dose of H2O2 to 5x-25x further reduced fibril
formation by ~40-60% depending on the exact dose. With large doses (500x and 1000x)
of H2O2, the ThT signal was reduced by ~75-80% compared with control.
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While ThT assays indicate that the oxidative environment provided by H 2O2
reduces fibril formation, these assays do not provide direct information on aggregate
morphologies and species beyond fibrils. As a result, AFM assays were performed using
a GST/mutant htt-exon1 fusion protein containing a 46 residue long polyQ domain that
46Q (htt-exon1(46Q)). Incubations of htt-exon1(46Q) (20 µM, 37°C) were treated with
H2O2 at various protein to peroxide ratios ranging from 1:5 to 1:1000. Control incubations
of htt-exon1(46Q) in which no peroxide was added were also prepared. Aliquots were
taken from each incubation at 1, 3, 5, and 8 h and deposited onto mica for AFM imaging
and analysis (Fig. 3.2). Fibrils were present and increased in occurrence with time under
all conditions; however, the extent of fibrillization appeared reduced with increasing dose
of H2O2 (Fig. 3.2A). In the absence of H2O2, fibrils were observed within 1 h of incubation.
With time, fibrils appeared longer and were predominately clustered together into large
bundles. Similar patterns of fibril formation were observed with 5x and 50x treatments of
H2O2; although, bundling of fibrils was less prominent compared with control. When H2O2
treatments were increased to 200x and 1000x, fibrils were still observed, but large
bundles were mainly absent.
To quantify this observation, all AFM images were analyzed using a combination
of features in WSxM58 and automated scripts that were written in Matlab. WSxM was used
to measure fibril contour lengths. Automated Matlab scripts were written to identify
individual aggregates and measures a variety of other morphological features. For these
automated measurements, fibrils were defined as features with a height greater than 2.5
nm and occupying an area in the image of at least 10,000 nm 2. The identified features
were manually inspected to exclude non-fibrillar structures (large amorphous structures)
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from any further analysis. A greater number of fibrils per µm2 (based on the above criteria)
was observed with increasing H2O2 dose at each time point (Fig. 3.2B); however, this raw
count of fibrils does not accurately reflect the fibril load under the different conditions. This
is due to fibrils under different conditions having distinct morphological features. That is,
the proclivity of fibrils to bundle in the absence of or low doses of H 2O2 created
inaccuracies in fibrils counts. For the control and 5x H2O2 incubations, the number of
fibrils per area fluctuates, but stays relatively consistent throughout the experiment. With
50x H2O2, the number of fibrils initially increases but drops at later time points. This
coincides with the appearance of fibril bundles. With 200x and 1000x H 2O2 treatments,
the number of fibrils steadily increased. As these conditions did not display excessive
bundle formation at later time points, the fibril count does not display a drop. Additionally,
the contour length of fibrils drastically decreased with increasing dose of H2O2 (Fig. 3.2C).
Initially, the fibrils observed after 1 h of incubation were similar in contour length under all
conditions; however, fibril elongation was severely stunted with increasing H2O2
treatment. The mean fibril length at 8 h for incubations of htt-exon1(46Q) without H2O2 or
with a 5x dose of H2O2 were both near 2 µm; however, fibrils formed in the presence of
200x or 1000x H2O2 were on average shorter than 500 nm. Due to these morphological
differences across conditions, the average surface area covered by fibrils was determined
to obtain a more accurate measure of fibril load across the different conditions (Fig. 3.2D).
Largest fibril area formed by the control (htt-exon1(46Q), no oxidation) was normalized
and the fibril areas from other conditions were reported relative to the control. Based on
this analysis, the extent of htt fibril formation clearly decreases with increasing H2O2
concentration, consistent with the ThT assay. The large error bars associated with the
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fibril area coverage of the htt-exon1(46Q) control and the 5x H2O2 incubations is due to
the localization of massive fibril content due to bundling. Collectively, these observations
suggest that oxidation of htt-exon1(46Q) interferes strongly with fibril elongation. That is,
a similar number of individual fibrils appeared after 1 h of incubation for all conditions
when bundling did not interfere with the accuracy of fibril counts. At high H2O2 doses
(200x and 1000x) the number of fibrils readily increased with time to similar extents, but
these fibrils remained short compared to their counterparts without or with low doses of
H2O2.
With the potential for oxidative conditions to interfere with fibril elongation, the
height (or thickness) of fibrils under the different conditions was analyzed to determine if
oxidation may be impacting the ultrastructure of fibrils. Height profiles were drawn across
single fibril strands and fibril bundles (Fig. 3.2E). Due to extensive bundle formation,
single strands for incubations without and with low doses of H 2O2 were often identified
protruding from bundles. Across all oxidation conditions, no apparent height difference
was observed for single strand fibrils. Single fibrils ranging from 5-8 nm in height were
readily observed across all conditions and time points. This suggests that despite
differences in the rate of formation and elongation that the fibrils under all conditions likely
have a similar polyQ core structure, which has been identified by several ssNMR
studies.61,62 As expected, fibril bundles were much thicker than single strands, reaching
25-30 nm in height.
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Figure 3.2: Oxidation alters the aggregation of htt. (A) Representative ex situ AFM
images of aliquots of htt-exon1(46Q) (20 µM) with H2O2 to achieve various final H2O2
concentrations of 0, 100 µM, 1mM, 4mM and 20 mM. Aliquots were sampled at 1,3,5 8
h. (B) Analysis of fibril population. Fibrils were counted at the different time points and
presented as fibrils/µm2. (C) Analysis of fibril length using WSxM. Fibrils were traced to
obtain the average fibril length for each condition. (D) Analysis of area covered by fibrils.
These values were normalized to the fibril covered by htt control (no oxidation) at 8 h.
(E) Height profiles of fibrils. The height profiles of fibril strands and bundles are shown
on different height scales. (F) Oligomers population analysis. Oligomers were identified
using automated scripts written in matlab. Oligomers are defined as globular features
taller than 1.0 nm and having coverage area between 500-10000 nm2. (G) Analysis of
oligomers height. Oligomers from all time points were combined per condition and the
heights of the combined data is presented.
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3.3.2 Oxidation promotes htt oligomerization. Having established that oxidation
suppressed fibrillization, AFM images were next analyzed for potential changes in
oligomer formation. Again, using automated scripts in Matlab, oligomers were identified,
and morphological features of these oligomers were determined. For this analysis,
oligomers were defined as any feature taller than 1.0 nm with an occupied area of 50010,000 nm2. Due to the small size of oligomers in the images presented in Fig. 3.2,
zoomed in, representative images of oligomers obtained at 1 and 3 h for all conditions
are provided in Fig. 3.3. The population of oligomers observed in incubations of httexon1(46Q) alone or with 5x H2O2 were relatively steady with less than 20 oligomers/µm2
at each time point (Fig. 3.2F). Higher oxidation conditions (50x – 1000x) generally
increased the oligomer populations. At 50x H2O2, htt oligomers increased for up to 5 h
(Fig. 3.2F) with a marked drop off at 8 h. This decrease roughly correlates with an
increase in fibril load previously discussed. At 200x H2O2, the oligomer population surged
at 3 h, resulting in a large, stable population of oligomers at 5 and 8 h. A similar large,
stable oligomer population was apparent with 1000x H2O2 throughout the incubation.
These observations suggest that suppression of fibril elongation due to exposure to
increasing concentration of H2O2 allows for the formation of a larger oligomer population.
To determine if this change in oligomer population size could be associated with distinct
oligomer types, oligomer morphological features were compared across the different
incubation conditions. The height of each oligomer was obtained using the same Matlab
script, but by determining the peak pixel of every identified oligomer. The height and
diameter of each individual oligomer were used to construct correlation plots (Fig. 3.2G).
With a 5x dose of H2O2, oligomer morphology was indistinguishable from control.
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However, with increasing H2O2 treatment, the distribution of oligomer morphologies
broadens in the correlation plots. Collectively, the presence of higher oxidant
concentrations increased the population and size of htt-exon1(46Q) oligomers.

Figure 3.3: Oxidation of htt-exon1(46Q) promoted oligomerization. Zoomed in
images at 1 and 3 h showing increased oligomerization with increase in oxidation. 20 M
htt-exon1(46Q) was incubated without and with 0.1, 1, 4 and 20 mM H2O2.

3.3.3 Oxidation reduces htt fibrilization in the presence of lipids. As a large
proportion of htt is associated with lipid membranes in vivo and lipids influence htt
aggregation,37,63–65 the impact of oxidative environments on htt aggregation in the
presence of TBLE vesicles was determined. The fibrillization of the Nt17-Q35-P10 peptide
in the presence of TBLE vesicles (1:20 peptide to lipid ratio) and various doses of H2O2
was monitored using the ThT assay (Fig. 3.4). The aggregation of Nt17-Q35-P10 in the
absence of TBLE vesicles or H2O2 was used as a control. Consistent with previous
reports,50,66 TBLE suppressed fibrillization, as the ThT signal was reduced by ~60%
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relative to the control. Addition of H2O2 to Nt17-Q35-P10 incubations with TBLE vesicles
further reduced fibrillization in a dose dependent manner. The ThT signal associated with
the addition of 1x H2O2 to the condition with just the addition of TBLE vesicles was
reduced by ~50%. 5x and 12.5x H2O2 treatments reduced the ThT signal by ~60%. Larger
doses of H2O2 prevented any increase in ThT signal.

Figure 3.4: ThT analysis of oxidized and unoxidized Nt17-Q35-P10 peptide
aggregation in the presence of lipid vesicles. Aggregation of Nt17-Q35-P10 (20 M)
monitored in the presence and absence of TBLE vesicles (~400 M). Samples containing
TBLE were further subjected to various oxidation conditions using H2O2 to achieve final
H2O2 concentrations of 0, 20 µM,100 µM, 250 µM, 500 µM, 10 mM, and 20 mM.

Due to the presence of two oxidizable methionine residues in Nt17, H2O2 could be
altering the interaction of htt with the TBLE. Therefore, the impact of H2O2 on the ability
of htt-exon1(46Q) to bind the TBLE vesicles was determined by a polydiacetylene (PDA)
lipid binding assay. PDA is a lipid moiety that is readily incorporated with other lipids into
vesicles. Photo-cross-linking of the PDA creates vesicles that are sensitive to mechanical
perturbations associated with the direct interaction of proteins with the lipids. This
sensitivity results in a color change from blue to red that can be monitored
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spectroscopically as a colorimetric response (CR). Here, TBLE/PDA lipid vesicles were
exposed to htt-exon1(46Q) in the presence of various doses of H2O2. H2O2 did not invoke
a CR response in the PDA assay in control experiments, and these controls were
incorporated into the calculation of the CR based on Eq. 1. Based on the PDA assay,
H2O2 did not alter the extent of interaction of htt with TBLE lipid vesicles; although, there
appears to be a slight lag in the htt/lipid interaction with treatment with 1000x H2O2 (Fig.
3.5).

Figure 3.5: PDA/TBLE lipid binding assay of htt-exon1(46Q) exposed to no or
various H2O2 concentrations. The colorimetric response was calculated as a function
of time upon exposure to 20 M htt-exon1(46Q) (deep blue) incubated at 25 °C and in
the presence of 0.1 mM (orange), 1 mM (grey), 4 mM (light blue), 20 mM H2O2 (yellow).

Similar to experiments without lipid, the impact of oxidation on htt aggregation in
the presence of lipids was further investigated using AFM. Incubations of htt-exon1(46Q)
(20 µM, 37°C) with TBLE vesicles (protein to lipid ratio of 1:20) were treated with H2O2 at
various protein to peroxide ratios ranging from 1:5 to 1:1000. In addition to control
incubations of htt-exon1(46Q) with TBLE vesicles in which no peroxide was added, a
control incubation of htt-exon1(46Q) with pre-oxidized TBLE vesicles was also performed.
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Figure 3.6: Presence of lipid vesicles alter the aggregation of oxidized htt.
Unoxidized TBLE vesicles were incubated with htt-exon1(46Q) in the presence of final
H2O2 concentrations of 0, 100 µM, 1mM, 4mM and 20 mM. Oxidized TBLE vesicles were
incubated with htt-exon1(46Q) with no additional H2O2. Aliquots were sampled at 1,3,5 8
h. (A) Representative ex situ AFM images of all experimental conditions. (B) Analysis of
fibril population. Fibrils were counted at the different time points and presented as
fibrils/µm2. (C) Analysis of fibril length using WSxM. Fibrils were traced to obtain the
average fibril length for each condition. (D) Analysis of area covered by fibrils. These
values were normalized to the fibril covered by htt incubated with unoxidized TBLE
(control, no oxidation) at 8 h. (E) Height profiles of fibrils. The height profiles of fibril
strands and bundles are shown on different height scales. (F) Oligomers population
analysis. Oligomers were identified using automated scripts written in matlab. Oligomers
are defined as globular features taller than 1.0 nm and covering 500-10000 nm2. (G)
Analysis of oligomers height. Oligomers from all time points were combined per condition
and the heights of the combined data is presented.
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That is, the htt remained unmodified. For this control, TBLE was treated with the same
concentration of H2O2 used for the 1000x condition for 3 h. Residual H2O2 was removed
via lyophilization, and the lipid was reconstituted for these incubations. Aliquots were
taken from each incubation at 1, 3, 5, and 8 h for AFM analysis (Fig. 3.6). Comparing the
AFM images of unoxidized htt-exon1(46Q) without (Fig. 3.2A) and with vesicles (Fig.
3.6A) demonstrated that TBLE suppressed fibril formation. Without H2O2 or with 5x H2O2,
fibril bundles were still observed after 8 h of incubation with TBLE vesicles (Fig. 3.6A),
but to a lesser extent compared to when vesicles were absent (Fig. 3.2A). With increasing
H2O2 concentration, the fibril load in the AFM images appeared to decrease. Interestingly,
oxidized lipid suppressed fibril formation to a similar extent. With the 1000x H2O2
treatment, apparent fibrils developed a halo-like feature around their periphery that was
not observed under other conditions (Fig. 3.2A, and Fig. 3.7). This suggests that the
combination of lipid species present in TBLE and the high concentration of peroxide alters
the peripheral structure of fibrils. This could potentially be due to incorporation of lipids
onto the exterior of fibrils or unstructuring of the flanking sequences that encapsulate the
polyQ fibril core.
The fibril load across the incubation conditions were quantified as before by
determining the number of fibrils per µm2, fibril contour length, and the surface area
covered by fibrils (Fig. 3.6B-D). As was observed in the absence of lipids, the actual
number of discrete fibril aggregates increased with H2O2 dose, but fibrils formed with
increasing H2O2 concentration were significantly shorter in length. Exposure of
unmodified htt to pre-oxidized lipid result in an intermediate increase in fibril population
compared to control, but to significantly smaller extent than incubations where the
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peroxide was present. Pre-oxidized lipid also reduced fibril length relative to incubations
of htt in the absence of H2O2 or 5x H2O2. Based on the area coverage of fibrils, there was
a loose trend of decreased fibril load with increasing peroxide concentration in the
presence of vesicles; however, this trend breaks down with 1000x H2O2 treatments as
these fibrils developed previously mentioned halo around their periphery, which increased
the area associated with these aggregates (Fig. 3.6D). Compared with other conditions
at similar time point, only htt-exon1(46Q) treated with 1000x H2O2 in the presence of
vesicles formed these unique features (Fig. 3.7). Pre-oxidized lipids had a similar fibril
load to control.

Figure 3.7: Peripheral features formed around htt-exon1(46Q) at extremely high
oxidant concentration. Incubations of 20 M htt-exon1(46Q) with 20 mM H2O2 (1000x)
revealed some halo features surrounding fibrils after 8 h. Images from htt-exon1(46Q)
incubations with 4 mM H2O2 (200x) after 8 h are shown for comparison.

Next, we measured the height profiles of the fibrils formed. Compared to similar
incubations without lipid, incubations at low oxidant concentrations in the presence of
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TBLE often formed fibrils strands that overlap after 8 h. Single fibrils strands formed in
the presence of TBLE vesicles with up to 50x H2O2 were similar in thickness to those
formed in the absence of lipids, and regions of fibril bundling were as tall as 20-25 nm.
However, fibril accumulation/bundling was absent in incubations with higher oxidant
concentrations. Single fibril strands formed in the presence of higher H2O2 concentration
(greater than 200x) were less thick compared to fibrils formed in the absence or lower
doses of H2O2, as profiles indicated that these fibrils were typically 3-5 nm in height,
suggesting that the morphology of fibrils formed are altered under high oxidation
conditions; however, this is difficult to assess due to the significant suppression of fibril
formation under these high oxidative conditions. Supporting the notion that fibril structure
is altered with high levels of H2O2 is the afore mentioned peripheral halo observed around
fibrils formed in the presence of TBLE and 1000x H2O2.
3.3.4 Oxidative environments influence oligomerization in the presence of lipid
vesicles. As oxidation of htt-exon1(46Q) promoted oligomerization in the absence of
lipids, the impact of H2O2 on oligomer formation in the presence TBLE vesicles was
investigated. Oligomers in AFM images of incubations of htt in the presence of TBLE
vesicles and various treatments of H2O2 were analyzed using the previously described
automated Matlab scripts and criteria. Higher resolution in images of htt-exon1(46Q)
oligomers formed in the presence of TBLE vesicles for different incubations in the
presence of TBLE vesicles are provided in Fig. 3.8. Under low oxidation conditions (no
oxidation, and 5x), oligomer population were less than 40/m2 across all time points (Fig.
3.6F). This represents an increase in oligomers associated with the presence of lipids
compared to the same conditions without lipids (Fig. 3.2F). At 50x H2O2 concentration,
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the oligomer popular was increased significantly to ~60/m2 at all time points. This was
also larger than was observed for 50x H2O2 without lipids. While 200x and 1000x H2O2
treatments increased the oligomer population in the presence of TBLE vesicles relative
to incubations of unmodified htt in the presence of lipids, the number of oligomers at this
level of peroxide was smaller compared to incubations of 50x H2O2 . In addition, the
oligomer population formed in the presence of 200x and 1000x was smaller in the
presence of TBLE vesicles (Fig. 3.6F) compared to the absence of TBLE vesicles (Fig.
3.2F). Similar to the absence of lipids, treatment with 50x H2O2 or larger promoted a
broader distribution of oligomer size, i.e. a subset of slightly larger oligomers. However,
broadening of the oligomer morphology distribution was not as pronounced in the
presence of TBLE vesicles (Fig. 3.6G).
3.3.5 Oxidation alters htt aggregation directly on the TBLE bilayer surface. While
both ThT assays and ex situ AFM data revealed that oxidation influences htt aggregation
in the presence of TBLE vesicles, these assays only measure aggregation throughout the
bulk of the solution. That is, they do not distinguish between aggregation occurring at the
membrane interface and in solution. Therefore, in situ AFM experiments were performed
to monitor aggregation directly on a supported TBLE bilayer to understand how oxidation
impacts aggregation on the membrane surface. Supported lipid bilayers were formed via
vesicle fusion. Three different conditions were investigated. Smooth bilayers (as
determined by AFM) were exposed to unmodified htt-exon1(46Q) proteins or httexon1(46Q) with 1000x H2O2. Control experiments were performed to confirm that
exposure to H2O2 alone did not alter bilayer morphology or integrity (Fig. 3.9). In addition,
supported TBLE bilayers that had been pre-oxidized were formed and exposed to
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unmodified htt-exon1(46Q). To cleave the GST moiety, Factor Xa was incubated with the
GST-exon1 fusion protein on ice for 90 min before the protein was exposed to any
supported bilayer. The final concentration of htt-exon1(46Q) in the AFM fluid cell was 10
µM.
Across all three conditions, distinct morphological changes were observed on the
supported lipid bilayers. In the absence of any H2O2, small oligomers of htt-exon1(46Q)
quickly appeared on the bilayer surface (within the first 30 min after exposure, Fig. 3.10A).
With time, the bilayer surface around these oligomers displayed a rougher morphology
(as can be seen from height profiles, Fig. 3.10B), consistent with disruption of the bilayer
packing order. These regions became rougher (due to continued accumulation of
additional htt) and more prominent with time (occupying ~25-35% of the surface area
within 150 min of exposure, Fig. 3.10A). In the presence of 1000x H2O2, exposure to httexon1(46Q) invoked a distinct morphological change in the bilayer compared with control,
especially up to ~80 min of exposure (Fig. 3.10B). While some small oligomers appeared
on the surface, these were associated with raised, plateau-like regions of the bilayer that
only appeared under this condition. These regions did not appear in bilayers only exposed
to H2O2 (or as will be seen in pre-oxidized bilayers), indicating that the combination of
exposure to peroxide and htt were required to invoke the formation of these domains.
Within ~80-100 min after exposure to htt, these plateau-like regions collapsed into a highly
granular, disrupted morphology that displayed clear holes within the bilayer. With time,
these holes were filled in as more htt accumulated into these regions. Similar to the control
experiments, ~25-35% of the bilayer surface displayed alter morphology due to exposure
to htt in the presence of H2O2, indicating that despite the differences in morphology that
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the total interaction with the bilayer was similar in scale. This is consistent with the PDA
assay presented in Fig. 3.5. When pre-oxidized TBLE bilayers were exposed to
unmodified htt-exon1(46Q), the plateau-like regions were not observed. Rather, regions
with a granular morphology that were associated with htt oligomers developed on the
bilayer within 20-50 min (Fig. 3.10A-B). With time, these regions grew in size and
accumulated additional material.

Figure 3.8: Oxidation of htt-exon1(46Q) promoted oligomerization in the presence
of TBLE. Zoomed in images taken at 1 and 3 h showing increased htt-exon1(46Q)
oligomerization with increase in oxidation in the presence of TBLE. 20 M htt-exon1(46Q)
+ TBLE vesicles were incubated without and with 0.1, 1, 4 and 20 mM H 2O2. 20 M httexon1(46Q) was also incubated with pre-oxidized TBLE. Final TBLE conc. was 300
mg/ml.
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Figure 3.9: TBLE bilayers stability in the presence of H2O2. TBLE bilayers were
exposed to 20 mM H2O2 and imaged continuously for 7 h.

To further illustrate the morphological differences of the perturbed bilayer regions
associated with exposure to htt-exon1(46Q) under all three conditions, correlation plots
of the mean height of disrupted regions vs the mean length across the disrupted regions
were constructed (Fig. 3.11). These features were measured for each individual disrupted
patch across multiple experiments and grouped by approximate time after exposure to
htt. As this analysis was performed on consecutive images obtained from single bilayers,
these data represent the evolution of these regions as a function of time. The mean height
was determined by averaging the height of all image pixels associated with an identified
region of altered morphology. The mean length was defined as the average between the
longest and shortest dimension across these features. Based on this analysis, there were
clear morphological differences associated with each condition (Fig. 3.11). In the absence
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Figure 3.10: Oxidation alters htt aggregation directly on the TBLE bilayer surface.
(A) Time-resolved in situ AFM images of supported bilayers of unoxidized and oxidized
TBLE exposed to 10 M of htt-exon1(46Q). Both htt-exon1(46Q) and TBLE were also
oxidized. (B) Height profiles of the conditions described in A. Blue and red lines represent
the profiles of different features observed. Green line represents the profile of the
undisrupted region of the bilayers.

97

Figure 3.11: Correlation plots showing mean length and mean height of htt
aggregates on the surface of TBLE bilayers. Distribution of mean length (average of
longest length and shortest length) and mean height of aggregates of (i) htt on unoxidized
TBLE (blue), (ii) oxidized htt and oxidized TBLE (red), and (iii) htt on ox TBLE (green)
were show at different times.

of H2O2, regions associated with altered morphology in the first 20-40 min of exposure
had a spread of mean height ranging from 1-5 nm but with a tighter distribution of mean
length below ~300 nm. This is predominately due to the abundance of discrete oligomers
that were not yet associated with large regions of perturbed bilayer morphology. In
contrast, at the 20-40 min time frame with both 1000x H2O2 present and with pre-oxidized
lipid bilayers, the mean height distributions were clustered around 0.5-2 nm, and the
distribution of mean length was much broader, extending beyond 1000 nm in several
cases. This is due to larger patches of disruption being observed. After 80-100 min of htt
exposure, the unoxidized and the pre-oxidized lipid conditions displayed similar
correlations between mean height and length. This is due to roughened bilayer
morphology developing around discrete oligomers in the unoxidized condition and the
continued development of grainy patches forming on the pre-oxidized lipid. With the
1000X H2O2 condition, there was a clear difference in the correlation plot at 80-100 min
as the plateau-like domains collapsing created a clear shift in the mean height
(predominately < 1 nm). As these disrupted morphological patches on the supported
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bilayer are all susceptible to accumulation of additional protein, the correlation plots for
all three conditions have significant overlap after 140-160 min of exposure. Together,
these results suggest that the aggregation of htt-exon1(46Q) is specifically altered at the
lipid interface by oxidation of both the protein and the lipid.
3.4 Discussion
Oxidative stress presents in a number of neurodegenerative diseases associated
with amyloid formation,67 and oxidation of amyloid-forming proteins alter aggregation and
aggregate stability.54,68,69 While this study focused on htt-exon1, oxidation of a cysteine
residue in an N-terminal fragment of htt longer than exon1 promotes oligomerization. 70 In
a shorter synthetic htt peptide containing Nt17 residues and various lengths of polyQ
stretches, oxidation of M8 to a sulfoxide prevents aggregation.19,51 This observation is
consistent with our findings that exposure to H2O2 decreases fibril load in a dose
dependent manner while promoting increased number of oligomers. With large doses of
H2O2, the actual number of discrete fibrils observed was larger, but these were
significantly shorter, suggesting that fibril elongation was being impacted by the presence
of peroxide. Similar to observation under other conditions that reduce htt fibril
formation,43,66 the oligomers appeared larger as fibril suppression was enhanced by H2O2,
suggesting that some conditions blocking fibril elongation can lead to a slight swelling of
oligomer size. A variety of effects on aggregation have been associated with htt oxidation
in cellular environments, adding another level of complexity. Cells expressing htt with an
expanded polyQ stretch were more sensitive to H2O2 treatment compared with cells
expressing non-pathogenic length htt.71 In the pathogenic cell line, H2O2 treatment
increased inclusion formation, suggesting that htt oxidation enhanced aggregation in a
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cellular environment; however, this may be related to impaired proteasome activity
associated with oxidative stress. Oxidation of M8 in preformed htt aggregates leads to
enhanced inter-aggregate interactions, modifying aggregate morphology. 72 Interestingly,
aggregated forms of htt were more readily oxidized than soluble htt. Oxidation of M8
dissociates htt from the ER membrane, creating soluble htt that is susceptible to
phosphorylation, increasing nuclear retention and inclusion formation. 44 Collectively,
these observations suggest oxidation of Nt17 alter htt’s interaction with other cellular
factors that influence aggregation. With htt being highly associated with membranes in
vivo and the Nt17’s ability to bind membranes, lipids represent one of these potential
cellular factors.
The combination of TBLE and H2O2 further modified htt aggregation. Peroxide
continued to suppress fibril formation in a dose dependent manner in the presence of
TBLE, and the 1000x H2O2 treatment caused a peripheral halo, potentially comprised of
lipid components, to develop around fibrils after 8 h of incubation. The presence of TBLE
vesicles reduced the enhancement of htt oligomers associated with exposure to H 2O2 in
their absence. That is, the number of oligomers did not increase as significantly with a
much less pronounced swelling of oligomer size as a function of H2O2 dose. The ability of
TBLE to stabilize discrete sizes of htt oligomers has been observed before with an Nt 17Q35 peptide34 and with acetylated htt-exon1.43 In particular, acetylation increased oligomer
size compared to unmodified htt-exon1 in the absence of lipids, but oligomers were similar
in size on TBLE bilayers regardless of acetylation state.43 The direct observation, via in
situ AFM, that the presence of H2O2 alters the initial htt-induced morphological changes
of TBLE bilayers demonstrates the complexity of htt aggregation in different
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environments. Lipid peroxidation was a contributing factor influencing htt aggregation
regardless of the oxidation state of htt itself. When pre-oxidized TBLE was exposed to
unmodified htt-exon1, morphological changes on the bilayer also varied from unoxidized
controls. Specifically, the accumulation of htt within these altered regions of the bilayer
was enhanced. This enhancement may be an indication of increased membrane defects
associated with lipid peroxidation that leads to enhanced membrane fluidity.73 For
example, when lipids containing POPC and cholesterol were rapidly oxidized, domains of
disordered oxidized lipids form.74 Oxidized lipid tails can migrate toward hydrophilic head
groups,75 creating additional membrane defects that may be susceptible to htt
accumulation. Determining all the factors influencing aggregation in vivo is daunting, but
the interfaces between subcellular membranes and the cytosol represent a unique
environment that can promote unique aggregation pathways. 37,76
Amphipathic

α-helical

motifs

commonly

function

to

sense

membrane

curvature,77,78 and Nt17 displays a preference for curved membranes in vitro.79 The
binding of amphipathic α-helical motifs to lipid membranes are often regulated by PTMs.
In this regard, the large variety of PTMs that occur in Nt17 may play a role in both htt’s
normal functions and toxic gain of function associated with polyQ expansion. For
example, phosphorylation of Nt17 regulates nuclear export of htt30,80 and promotes
clearance of htt via the proteasome and lysosome.45 PTMs in Nt17 indeed manipulate its
helical content.81 Oxidation of M8 in Nt17 functions as a ROS sensor, altering htt’s affinity
for the ER membrane, and triggering localization to the nucleus.44 Despite this effect of
promoting detachment from the ER, oxidation of M8 promoted α-helical content.44
Molecular dynamic simulations suggest that when Nt17 is pre-folded into an α-helix that
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it binds membranes more readily.82 However, M8 is positioned facing toward the
hydrophobic core when bound to POPC bilayers,21 and the advanced hydrophilicity
associated with oxidation would make this positioning less favorable. Indeed, oxidation
reduces the affinity of Nt17 for LPC/LPG micelles by ~3-4 fold; however, the α-helix of
micelle-bound NT17 extends by an additional 2 residues. 51 Based on these reports and
our observation of altered aggregation of H2O2 treated htt, we expected to observe a
decreased binding of htt with TBLE upon oxidation. However, the oxidation did not
significantly reduce the extent of htt/lipid interaction. The root cause of this discrepancy
may lie in the unique lipid systems used, as lipid composition heavily influences htt
aggregation as will be discussed in the next paragraph. Despite a similar magnitude of
htt/lipid interaction, the initial htt aggregation process occurring directly on the TBLE
bilayer surface was clearly altered based on in situ AFM assays.
Selectivity of Nt17 for different subcellular membranes throughout cells may derive
from a combination of varying lipid composition and PTMs of htt. Once bound, these
unique lipid environments exert influence on the aggregation process through their
physicochemical properties, as observed in a variety of amyloid/membrane interactions. 76
TBLE and other brain extracts slow fibril formation.50,66,83 Adding exogenous cholesterol,
sphingomyelin, or gangliosides to TBLE modifies htt aggregation directly on supported
bilayers, resulting in the appearance of unique morphological and mechanical changes.
POPC/POPS lipid systems promote htt fibril formation and a unique aggregation
mechanism in comparison to aggregation occurring in bulk solution. 28,37 Zwitterionic lipids
POPC and POPE mildly altered the rate of htt aggregation, with POPC mildly enhancing
aggregation and POPE mildly slowing it.41 However, anionic lipids (POPG and POPS)
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strongly accelerate fibril formation, and POPG promoted a unique fibril morphology. 41 The
variation in how specific lipids interact with htt via Nt17 represents a plausible explanation
as to why oxidation reduced htt affinity for LPC/LPG micelles, 51 while we observed no
significant reduction in the ability of oxidized htt to bind TBLE. The ability of a single PTM
in Nt17 to influence htt/lipid binding in a lipid dependent manner is observed in studies
using phosphomimetic mutations in htt-exon1.50 Phosphomimetic mutations at T3 and
S13 significantly reduced the binding of htt-exon1 to TBLE vesicles, but these mutations
had no significant impact on the ability of htt to bind POPC or POPG vesicles.
In summary, H2O2 reduced total fibril formation of htt in a dose dependent manner,
and reduced fibril elongation appeared to be a prominent feature of this phenomenon.
This promoted a larger population of oligomers with slightly altered morphology. In the
presence of TBLE vesicles based on bulk solution assays, H 2O2 retained its ability to
reduce htt fibril load in a dose dependent manner; however, the impact on oligomer
formation was reduced. This occurred despite no change in the bulk affinity of htt for TBLE
vesicles. Nevertheless, oxidation environments altered htt-induced morphological
changes and aggregation directly at the bilayer surface.
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4 Future directions for mitigating huntingtin aggregation and toxicity
4.1 Introduction
Huntington’s disease is a fatal autosomal dominant neurodegenerative disease
caused by an expansion mutation of polyglutamine (polyQ) stretch located near the Nterminus of the huntingtin (htt) protein. Expansion of the polyQ domain correlates with htt
aggregation into oligomers, fibrils, and amorphous aggregates. Ultimately, these
aggregate species accumulate to form inclusion bodies in the nucleus and cytosol.1–3
Toxicity has been attributed, both individually and collectively, to all these aggregate
species.4–9 Due to the potential toxic activity of all these unique aggregate species,
unraveling the complexity of the heterogeneous htt aggregation process would prove
critical in understanding htt-related toxic mechanisms. Importantly, several cellular factors
such as the presence of lipid membranes and post translational modification of htt
profoundly contribute to the aggregation process.1 In this dissertation, the impact of
mitochondrial lipids and oxidation on htt aggregation were determined.
In the cellular environment, lipid membranes enclosing organelles provide unique
surface/cytosolic interfaces. While htt localizes to numerous membranous surfaces,10,11
the interaction of htt with mitochondrial surfaces are thought to play a key role in HD, as
mitochondrial dysfunction is a marker in disease progression. Most studies focus on the
consequence to mitochondria integrity, dynamics, and function upon exposure to mutant
htt; 10,12–14 however, little is known about how the mitochondrial environment influences htt
aggregation. In Chapter 2, we sought to understand how the presence of MEFs and
mitochondrial membrane mimics impact htt aggregation. The presence of MEFs isolated
from brain or liver reduced htt fibrillization and promoted a unique oligomer morphology.
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Mitochondrial membrane mimic vesicles influenced aggregation in a similar fashion, that
is, reduction in htt fibril formation in the presence of OMM and IMM mimics. The IMM was
more effective at suppressing fibrillization. A systematic investigation into the difference
in the degrees of fibrillization inhibition by OMM and IMM implicated CL, a lipid unique to
mitochondria but more abundant in IMM, in playing a key role in reducing fibrillization.
Interestingly, direct observation of htt aggregation on the surface of OMM or IMM
demonstrated that morphological changes on the membranes were starkly different.
While htt formed granular, oligomeric and fibrillar aggregates on OMM, large domains of
htt that were void of distinct morphology developed on IMM. Collectively, these
observations suggest that the mitochondrial environment strongly influences htt
aggregation. These distinct aggregate species may play a role in htt-induced
mitochondrial dysfunction.
A major factor in HD and many other neurodegenerative diseases is aging, which
can be associated with consequential oxidative stress.15–18 Under stressed conditions,
there are more reactive oxidative species formed than consumed. This excess oxidant
load promotes oxidative PTM of proteins.19–21 In HD, the Nt17, or the 17 N-terminal
residues of huntingtin, contains methionine residues that are prone to oxidation. This
same region (Nt17) of htt functions as a membrane binding domain and plays a key role
in initiating the aggregation process. Thus, htt oxidation, like other PTMs in Nt17, may
have profound consequences for htt membrane localization. 22–24 However, little is known
about the impact of oxidation on htt aggregation. In Chapter 3, the aim was to determine
the impact of oxidative environments, using H2O2, on htt aggregation and membrane
interactions. As verified by Thioflavin T assay and ex situ AFM, increasing oxidant
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concentration progressively reduced the total amount of fibrils formed in the absence of
lipids. Fibrils formed under highly oxidative environments were shorter, suggesting that
oxidation impedes fibril elongation. However, higher oxidant concentrations increased
oligomer formation and stability. The presence of lipids (oxidized and unoxidized)
complicated the aggregation of htt in an oxidative environment. There was a reduction in
the total load of fibrils formed as H2O2 concentration was increased and the morphology
of the fibrils was altered. While the presence of lipids and H2O2 also facilitated the
formation of short fibrils, fibrillization was generally suppressed and a peripheral halo was
observed around the fibrils formed at very high oxidation concentration. Similarly, the
oligomers population in these oxidative environments were altered in comparison to htt
controls. Oligomerization of htt was promoted H2O2 by in the presence or absence of
TBLE vesicles. In addition, at the membrane interface, the presence of H2O2 influenced
morphological changes upon exposure to htt. In the absence of oxidants, htt deposited
as oligomeric aggregates that increased in both size and number with time. In contrast,
when both htt and TBLE were subjected to high oxidative environment, the formation of
plateau-like patches of htt deposits that were rich in granular and oligomer species were
formed. The exposure of htt to oxidized TBLE showed similar htt deposition that
recapitulates morphological features in unoxidized systems. That is, there were formation
of granular oligomeric aggregates that accumulated more aggressively. Taken together,
the work in Chapter 3 suggested that oxidation of htt alter the morphology of fibrils formed,
regardless of the presence or absence of lipids. In addition, in the presence of htt,
oxidative environment appeared to promote the formation of domains in TBLE bilayers.
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As research into a cure for HD continues, it is important to fully understand the
consequence of lipid synthesis, peroxidation and htt interactions in HD, and to discover
therapeutic approaches that will reduce htt toxicity. Based on the works presented in
Chapters 2 and 3, it becomes imperative to: 1) determine the impact of cardiolipin on htt
toxicity in cells; 2) investigate the effect of oxidation of some select lipids that make up
mitochondrial membranes, and the consequence on htt aggregation; 3) determine the
contributions of other cellular factors such as molecular crowding; and 4) understand how
protein/protein interactions impact htt aggregation.
4.2 Impact of Cardiolipin on htt toxicity
CL plays a crucial role in maintaining the integrity of mitochondrial membranes,
providing support, and being involved in mitochondria fission. Cardiolipin content may
vary per location in response to cellular stress. For example, CL becomes externalized
from the inner mitochondrial membrane to the outer membrane during mitophagy. 25,26
Unsurprisingly, CL decrease or alteration has been implicated in apoptosis27 and
numerous diseases28–31 including neurodegenerative diseases.32,33

Specifically, the

amount of CL in brain of transgenic Alzheimer’s Disease mice fall significantly compared
with non-transgenic mice.32 More recently, we have demonstrated that CL suppresses the
fibrillization of htt. As htt aggregation is central to HD pathology, and consensus on the
roles of the different aggregate species on htt toxicity is not yet in sight, it becomes
important to understand the role of this lipid in htt toxicity. If the strong correlation between
CL content and htt aggregation observed in vitro with ThT assay and ex situ AFM also
holds in vivo, and if this translates into reduced toxicity, CL content regulation may

115

become a therapeutic strategy for HD. A strategy to investigate this is to control the
synthesis of CL in cell lines expressing wild type and mutant htt.
4.3 Investigation of the role of oxidized lipids of mitochondria on htt aggregation
Mitochondria is a source of ROS, producing superoxide radicals which later
generate hydrogen peroxide34,35 during different stages of respiration. Mitochondria also
susceptible to oxidation as evidenced by lipid and protein peroxidation. 36–38 The most
abundant lipid in mammalian mitochondria is neutral PC, 39 which is susceptible to
oxidation.40 Also unique to mitochondria is cardiolipin with an anionic net charge and in
most instances a high degree of unsaturation in its acyl chains, which are consequently
prone to oxidation. The fluidity of membranes containing oxidized lipids increases. 41
There is also migration of the oxidized regions from the membrane interior to the surface, 42
promoting unique surface domains and defects. In Chapter 2, we showed that
mitochondrial membranes impact huntingtin aggregation. In Chapter 3, it was
demonstrated that oxidation also modifies htt aggregation and its ability to interact directly
with lipid membranes. With the production of ROS at mitochondrial surfaces, these two
chapters collectively point toward a need to understand how oxidation influences htt
aggregation in the presence of mitochondria. For example, will htt aggregation be
inhibited if some of the lipids of mitochondria are oxidized? (Fig. 4.1).
In addition, mitochondrial dysfunction is implicated in HD and it is a site of ROS
production, it would be beneficial to ascertain how oxidation of mitochondrial lipids impact
mitochondrial membrane integrity. This can be achieved by oxidizing separately PC (the
most abundant lipid in mitochondria) and CL (the unique mitochondrial lipid which often
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Figure 4.1. Determination of effect of oxidized lipids of mitochondria on htt
aggregation. Htt aggregates into oligomers and fibrils. In the presence of mitochondrial
membrane mimic (MM), fibrillization of htt was reduced (bottom arrow). The impact of
oxidized lipids of mitochondria (top arrow) is unknown.

exist with high degree of unsaturation in acyl tail) prior to vesicles and bilayers formation.
Experimentation can be performed as described in Chapter 2, that is, exposure of htt to
vesicles made from oxidized and unoxidized lipids of mitochondria. Aliquots of
aggregating mixtures can be drawn, deposited on mica, and imaged with AFM for
aggregates morphology determination. Also, the consequence of oxidized PC and CL on
the integrity of mitochondrial membrane can be investigated by forming bilayers from the
vesicles and probing bilayer surface with AFM for mechanical changes.
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4.4 How does crowding affect huntingtin aggregation?
In Chapters 2 and 3, we investigated the interaction of htt at membrane interfaces
using in situ AFM. The variations in the bilayers systems used include lipid composition
and chemical modifications. From the studies presented in the earlier chapters, the
deposition of htt to the surface of lipid bilayers varied, further supporting evidence about
the differences various membranes impact on protein aggregation. Various surfaces can
trigger conformational changes in proteins, hence steer the aggregation towards a unique
or different path as compared to aggregation in free solution. 43–49 Such changes may be
as a result of multiple interactions such as electrostatics and Van der Waals. 50 Aside from
the contribution of phase difference and interactions at membrane interfaces, crowding
of the protein environment also contributes to aggregation 51 through a variety of
mechanisms, i.e. excluded volumes effects.52 Excluded volume effects are the stearic
hinderances that exist on a macromolecule in relation to others as a consequence of the
coexistence of multiple macromolecules or crowders. In practice, movement is limited as
a result of excluded volumes, causing a molecule to experience less randomness or
entropy. Alteration in a thermodynamic property, such as entropy, of a protein may in turn
change the behavior of such macromolecule, and consequently, alter protein aggregation
and amyloid formation.53–55 The cytosol is crowded with various macromolecules such as
proteins, polysaccharides, DNA, and RNA.56 This creates the scenario where the most
physiologically relevant membrane interface is adjacent to a crowded aqueous
environment.
Huntingtin is mostly cytosolic but is also found in the nucleus. Intracellularly,
huntingtin exist with and interact with multiple organelles and proteins. Since several
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factors can alter the conformation and stability of proteins, and consequently their
aggregation, it is expected that an understanding of the aggregation of htt under a
controlled crowded environment will provide insights into the rate, and mechanism of htt
aggregation into different aggregate species. This hypothesis can be investigated using
inert macromolecular crowders such as dextran, Ficoll and PEG. We have performed
experiments aimed at understanding the aggregation of surfaces and membrane
interfaces with a crowded aqueous phase using in situ AFM. These experiments support
the notion that the crowded cytosol can influence aggregation at surfaces. For example,
when investigating the aggregation of a synthetic htt peptide mimic (Nt17Q35P10KK) on
mica, aggregation was inhibited in a crowder-dependent fashion (Fig 4.2A). In the
absence of crowders, Nt17Q35P10KK aggregates appeared as early as 9 min, forming
oligomers, and fibrils that increased with time. The addition of crowders caused reduced
aggregation on mica, leading to decreased coverage area of aggregates (Fig 4.2B). PEG
inhibited fibrillization of Nt17Q35P10KK the most, with only a few small oligomers observed
after 3 h. Ficoll and dextran also reduced aggregation of htt to various degrees.
When the mica surface was substituted with a bilayer of TBLE, a crowded aqueous
phase influenced, beyond the rate of aggregation, morphological changes associated with
exposure to htt (Fig. 4.3). With a non-crowded aqueous phase, htt formed oligomers that
increased in number and were associated with patches of increased roughness on the
bilayer surface (Fig. 4.3B). With a crowded aqueous phase, a variety of distinct
aggregation patterns were observed on the bilayer surface (Fig. 4.3A-C). Crowders’
presence promoted roughness of the membranes (Fig. 4.3B). With the addition of dextran
htt also formed oligomers that increased significantly in diameter with time (Fig. 4.3A, C).
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Figure 4.2. Comparison of Nt17-Q35-P10-KK aggregation on mica with different
macromolecular crowders in the aqueous phase. (A) Time-sequence, representative
in situ AFM images of Nt17-Q35-P10-KK (10 µM) aggregating on mica with buffer, dextran,
Ficoll, or PEG in the aqueous phase. The macromolecular crowder concentration was
100 mg/mL. As the height of features varied, the blue boxes represent areas of the image
that correspond to the color scale with blue font. (B) Quantification of the % surface area
covered by Nt17-Q35-P10-KK aggregates as a function of time. Error bars represent
standard deviation.

Ficoll promoted the formation of tall globular aggregates that swelled with time, and deep
holes eventually developed on the bilayer surface (Fig. 4.3A, C). With PEG, small
oligomers initially appeared, and the entire bilayer surfaces began to display enhanced
roughness (Fig. 4.3A, B). Large aggregates appeared after ~1 h and were accompanied
by an intense disruption of TBLE bilayer that caused exposure of the underlying mica
surface. Accordingly, htt disrupted a larger surface area in the presence of crowders (Fig
4.3 A, D). The highest percent disruption was observed with PEG, which also has the
highest degree of roughness.
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Figure 4.3. Comparison of htt-exon1(46Q) aggregation on supported TBLE bilayers
with different macromolecular crowders in the aqueous phase. Time-sequence,
representative in situ AFM images of htt-exon1(46Q) (10 µM) aggregating on supported
TBLE bilayers with buffer, dextran, Ficoll, or PEG in the aqueous phase. The
macromolecular crowder concentration was 25 mg/mL. As the height of features varied,
the blue boxes represent areas of the image that correspond to the color scale with blue
font. (B) Quantification of the RMS roughness of unperturbed (solid bars) and disrupted
(striped bars) regions of the bilayer. The RMS roughness of a bilayer prior to exposure to
htt-exon1(46Q) is provided by the purple bar. Error bars represent standard deviation. (C)
Height and diameter histograms of htt-exon1(46Q) aggregates as a function of time. (D)
Quantification of the % area of the bilayer disrupted by htt-exon1(46Q) as a function of
time. Error bars represent standard deviation.

4.5. Inhibiting amyloid formation through protein-protein interactions.
Aggregation of proteins are implicated in numerous neurodegenerative diseases.
In crowded cellular environments, these proteins are exposed to numerous influences
from various non-specific interactions with macromolecules such as polysaccharides,
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DNA, and even membranous surfaces. In amyloid formation, amyloidogenic proteins
misfold, precipitate and deposit in patients through protein-protein interactions. Since
proteins are mostly labile, such interactions can upset their stability and consequently
alter their aggregation rate. While most amyloids are formed by self-assembly of similar
proteins, protein-protein interactions between different proteins may also impact the
formation of aggregates. Many amyloid-forming proteins display a variety of specific
protein-protein interactions. For example, -synuclein, a protein whose aggregated forms
found in Lewy bodies is associated with PD, interacts with multiple proteins.

Figure 4.4. NUCB1 inhibited the aggregation of htt-exon1. Htt-exon1(46Q) (10 µM)
with and without NUCB1 (10 µM) were incubated for 8 h. Aliquots of incubations were
taken at various time points (1,3,5 and 8 h), deposited on mica and imaged with AFM.

122

-synuclein interacts with -synuclein, which it colocalizes with.57 Such interaction
impeded the self-assembly of -synuclein.57 In addition, the kinetics of aggregation can
also be altered through protein-protein interactions.58 -amyloid, one of the proteins
implicated in AD, can seed, and promote the aggregation of -synuclein.59 For all these
reasons, determining how protein-protein interaction influence aggregation may prove
important to understanding associated toxic mechanisms.
Nucleobindin1 (NUCB1) is a Golgi-resident protein that binds and controls calcium
homeostasis.60 A non-calcium binding variant of NUCB1 has been shown to reduce
amyloid formation in amyloidogenic proteins such as Human islet amyloid polypeptide 61
and -synuclein62 by stabilizing the protofibrils, or short soluble filamentous species which
are commonly formed by amyloid proteins. Therefore, it is plausible that NUCB1 could

Figure 4.5. NUCB1 inhibited the aggregation of Nt17-Q35-P10-KK. Nt17-Q35-P10-KK (10
µM) was incubated with and without NUCB1 (10 µM) for 3 h. Aliquots from incubations
drawn after 10 min and 3 h were deposited on mica and imaged with AFM.
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Figure 4.6. In situ tracking of Nt17-Q35-P10-KK in the presence of NUCB1. (A) Nt17Q35-P10-KK (10 µM) was incubated with and without NUCB1 (10 µM) and imaged
continuously for 119 min. (B) Analysis of the surface area covered by Nt 17-Q35-P10-KK in
the presence and absence of NUCB1.

have a similar aggregation inhibiting effect on htt. The validity of this hypothesis is
supported by preliminary studies. First, htt-exon1 incubated with NUCB1 displayed a clear
reduction in the amount of fibrils formed (Figure 4.4). Second, a similar study of
incubations of htt-exon1 mimic (Nt17-Q35-P10-KK) and NUCB1 showed no fibrils formed
after 3 h of incubation with even though Nt17-Q35-P10-KK aggregated in the absence of
NUCB1 was significant at similar time point (Fig 4.5). Third, in situ AFM studies tracking
the aggregation of the synthetic htt mimic peptide (Nt17-Q35-P10-KK) on mica revealed a
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clear reduction of aggregation (Figure 4.6). This demonstrates that protein-protein
interactions represent another mitigating factor in htt aggregation.
4.6 Concluding remarks
The findings presented in this work demonstrate the relevance of membranous
surfaces and chemical modifications to htt aggregation and HD. We showed that AFM is
a valuable technique to study the morphology of aggregates derived from either exposing
htt to various membranes or subjecting htt to post translational modifications. It was
shown that the aggregation of htt is influenced not only by the presence of membranes,
but that composition of membranes also play an important role. Furthermore, we also
revealed that oxidation promoted oligomerization and distinct fibrillar morphology, both of
which provide insights into the role of increased oxidative environment in HD
pathogenesis.
The ideas and results presented in this chapter further emphasized the complexity
of htt aggregation and presented possible ways of mitigating it. Specifically, it was
suggested that CL which inhibited aggregation may have similar effect on htt toxicity. In
addition, it was demonstrated interactions of htt with other proteins or other
macromolecules have a variety of effects on htt aggregation. These investigations and
findings are directed towards understanding and inhibiting htt aggregation as a potential
therapeutic approach to HD.
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